Article(id=1256183395432915307, tenantId=1146029695717560320, journalId=1255847919539208197, issueId=1256183358493679805, articleNumber=null, orderNo=null, doi=10.13193/j.issn.1673-7717.2025.12.008, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=null, receivedDateStr=null, revisedDate=null, revisedDateStr=null, acceptedDate=null, acceptedDateStr=null, onlineDate=1777427060229, onlineDateStr=2026-04-29, pubDate=1765296000000, pubDateStr=2025-12-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1777427060229, onlineIssueDateStr=2026-04-29, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1777427060229, creator=13701087609, updateTime=1777427060229, updator=13701087609, issue=Issue{id=1256183358493679805, tenantId=1146029695717560320, journalId=1255847919539208197, year='2025', volume='43', issue='12', pageStart='1', pageEnd='258', issueExtLink='null', onlineDate='null', pubDate='null', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=1, specialIssue=null, createTime=1777427051344, creator=13701087609, updateTime=1777427760067, updator=13701087609, preIssue=null, nextIssue=null, ext={EN=IssueExt(id=1256186331126969089, tenantId=1146029695717560320, journalId=1255847919539208197, issueId=1256183358493679805, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1256186331126969090, tenantId=1146029695717560320, journalId=1255847919539208197, issueId=1256183358493679805, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null}, startPage=47, endPage=54, ext={EN=ArticleExt(id=1256183402093470120, articleId=1256183395432915307, tenantId=1146029695717560320, journalId=1255847919539208197, language=EN, title=Investigating Effect of Sanqi(Notoginseng Radix et Rhizoma)on Mitochondrial Energy Metabolism in Rats with Renal Fibrosis Based on Metabolomics, columnId=1256183361521967297, journalTitle=Chinese Archives of Traditional Chinese Medicine, columnName=Target on National Project, runingTitle=null, highlight=null, articleAbstract=
Objective

To study the effectof Sanqi(Notoginseng Radix et Rhizoma)onmitochondrial energy metabolism of rats with adriamycin induced kidney fibrosis with blood stasis.

Methods

Thirty rats were divided into 6 groups random ly,including normal group,model group,Sanqi(Notoginseng Radix et Rhizoma)low-dose group,Sanqi(Notoginseng Radix et Rhizoma)medium-dose group,Sanqi(Notoginseng Radix et Rhizoma)high-dose group and positive control group,with 5 rats in each group.Themitochondrial structure of rat renal tissue was observed by electron microscopy.The contents of adenosine triphosphate(ATP),adenosine diphosphate(ADP),adenosine monophosphate(AMP),the activities of Na+ -K+ -ATPase,Ca2+ -Mg2+-ATPase and the activities ofmitochondrial respiratory chain complex enzymeⅠ-Ⅳwere detected by chemical method.The metabolites of urine were analyzed by liquid chromatograph and mass spectrometer.The differential metabolites were enriched by Kyoto Encyclopedia of Genes and Genomes(KEGG)metabolic pathway.

Results

Under electron microscope,the mitochondrial structure of renal tissue in the model group was incomplete,and Sanqi(Notoginseng Radix et Rhizoma)could maintain the homeostasis of renalmitochondrial structure.Sanqi(Notoginseng Radix et Rhizoma)could increase the mitochondrial ATP contentof the renal tissue,the activities of Na+-K+-ATPase,Ca2+-Mg2+-ATPase andmitochondrial respiratory chain complex enzymeⅠ-Ⅳ.Sanqi(Notoginseng Radix et Rhizoma)could reduce the contents of mitochondrial ADP and AMP of renal tissue.After analysis and comparison among the groups,11 different urine metabolites were screened,including ferulic acid,forin,arabitol,acetamide,biotin,allantoic acid,6-methylmercaptopurine,4-hydroxy-2-quinolone,aminopentanedioate,6-methyladenine and moupinamide.Further enrichment of urinemetabolites by KEGG in different experimental groups showed that the aldosterone-regulated sodium reabsorption signal pathway was significantly different.

Conclusion

Sanqi(Notoginseng Radix et Rhizoma)regulates the differential urine metabolites and raldosterone-regulated sodium reabsorption signal pathway.Sanqi(Notoginseng Radix et Rhizoma)can improve mitochondrial energy metabolism and renal fibrosis in chronic kidney diseases(CKD)rats with blood stasis bymulti-target and multi-pathway.

, correspAuthors=null, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, authorCompany=null, fund=null, authors=null, authorsList=Zhimin HUANG, Liangxi LU, Jinyu WU), CN=ArticleExt(id=1256183549380649320, articleId=1256183395432915307, tenantId=1146029695717560320, journalId=1255847919539208197, language=CN, title=基于代谢组学探讨三七对肾纤维化大鼠线粒体能量代谢的影响, columnId=1256183362172142382, journalTitle=中华中医药学刊, columnName=国家项目点击, runingTitle=null, highlight=null, articleAbstract=
目的

研究三七对血瘀证阿霉素肾纤维化大鼠线粒体能量代谢的影响。

方法

将30只SD大鼠随机分为6组:正常组、模型组、三七低剂量组、三七中剂量组、三七高剂量组、阳性对照组,每组5只。采用电镜观察大鼠肾组织线粒体结构,化学法检测肾组织三磷酸腺苷(Adenosine triphosphate,ATP)、二磷酸腺苷(Adenosine diphosphate,ADP)、一磷酸腺苷(Adenosinemonophosphate,AMP)含量、Na+-K+-ATP酶、Ca2+-Mg2+-ATP酶活性、线粒体呼吸链复合体酶Ⅰ~Ⅳ活性。采用液相色谱仪、质谱仪对尿液进行代谢物成分分析,获得代谢差异物后,进行KEGG代谢通路富集。

结果

电镜下可见模型组大鼠肾组织线粒体结构不完整,三七可以维持肾组织线粒体结构稳态。三七可以提高肾组织线粒体ATP含量、Na+-K+-ATP酶、Ca2+-Mg2+-ATP酶、线粒体呼吸链复合体酶Ⅰ、Ⅱ、Ⅲ、Ⅳ活性;降低肾组织线粒体ADP、AMP含量。进行三七低、中、高剂量组、模型组和正常组分析对比,筛查出11个差异尿液代谢产物,分别为Ferulic acid、Morin、Arabitol、Acetamide、Biotin、Allantoic acid、6-Methylmercaptopurine、4-Hydroxy-2-quinolone、Aminopentanedioate、6-Methyladenine、Moupinamide。进一步对各实验组动物尿液代谢物KEGG通路富集分析结果显示:醛固酮调控的钠重吸收通路差异具有显著统计学意义。

结论

三七通过调节差异尿液代谢产物的代谢,调控醛固酮调节Na+重吸收通路,从多靶点、多途径改善血瘀证慢性肾脏疾病(Chronic Kidney Diseases,CKD)大鼠的线粒体能量代谢,发挥抗肾纤维化作用。

, correspAuthors=null, authorNote=null, correspAuthorsNote=
吴金玉(1965-),女,广东广州人,教授、主任医师,博士研究生导师,博士,研究方向:中医药防治风湿免疫疾病。E-mail:
, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=rmTp9dxJQCO1Nbk52ghMrA==, magXml=YEPfntjwHZtgA8Ql/vbSOg==, pdfUrl=null, pdf=YspK3HogOMuyNa+KuyTR6w==, pdfFileSize=6694706, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=etdBvOYz85hGFDTfTLn8+A==, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=8qVB8tvnwgtrPseO3cTzdg==, mapNumber=null, authorCompany=null, fund=null, authors=

黄志敏(1988-),女,广西贵港人,主治医师,博士,研究方向:中医药防治风湿免疫疾病。

, authorsList=黄志敏, 陆良喜, 吴金玉)}, authors=[Author(id=1256183557274329542, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1256183558536815066, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, authorId=1256183557274329542, language=EN, stringName=Zhimin HUANG, firstName=Zhimin, middleName=null, lastName=HUANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.The First Affiliated Hospital of Guangxi University of Chinese Medicine,Guangxi Key Laboratory of Molecular Biology of Preventive Medicine of Traditional Chinese Medicine,Nanning 530023,Guangxi,China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1256183559388258791, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, authorId=1256183557274329542, language=CN, stringName=黄志敏, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.广西中医药大学第一附属医院,广西中医药防治医学分子生物重点实验室,广西 南宁 530023, bio={"content":"

黄志敏(1988-),女,广西贵港人,主治医师,博士,研究方向:中医药防治风湿免疫疾病。

"}, bioImg=null, bioContent=

黄志敏(1988-),女,广西贵港人,主治医师,博士,研究方向:中医药防治风湿免疫疾病。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1256183554904547742, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, xref=1., ext=[AuthorCompanyExt(id=1256183555210731936, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, companyId=1256183554904547742, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.The First Affiliated Hospital of Guangxi University of Chinese Medicine,Guangxi Key Laboratory of Molecular Biology of Preventive Medicine of Traditional Chinese Medicine,Nanning 530023,Guangxi,China), AuthorCompanyExt(id=1256183555386892707, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, companyId=1256183554904547742, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.广西中医药大学第一附属医院,广西中医药防治医学分子生物重点实验室,广西 南宁 530023)])]), Author(id=1256183560776573431, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1256183562001310217, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, authorId=1256183560776573431, language=EN, stringName=Liangxi LU, firstName=Liangxi, middleName=null, lastName=LU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.Ren'ai Branch of The First Affiliated Hospital of Guangxi University of Chinese Medicine,Nanning 530001,Guangxi,China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1256183563590951445, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, authorId=1256183560776573431, language=CN, stringName=陆良喜, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.广西中医药大学第一附属医院仁爱分院,广西 南宁 530001, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1256183556167033266, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, xref=2., ext=[AuthorCompanyExt(id=1256183556477411766, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, companyId=1256183556167033266, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Ren'ai Branch of The First Affiliated Hospital of Guangxi University of Chinese Medicine,Nanning 530001,Guangxi,China), AuthorCompanyExt(id=1256183556531937721, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, companyId=1256183556167033266, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.广西中医药大学第一附属医院仁爱分院,广西 南宁 530001)])]), Author(id=1256183565319004711, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=wujinyu0109@sina.com, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1256183567344853558, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, authorId=1256183565319004711, language=EN, stringName=Jinyu WU, firstName=Jinyu, middleName=null, lastName=WU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.The First Affiliated Hospital of Guangxi University of Chinese Medicine,Guangxi Key Laboratory of Molecular Biology of Preventive Medicine of Traditional Chinese Medicine,Nanning 530023,Guangxi,China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1256183568208880191, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, authorId=1256183565319004711, language=CN, stringName=吴金玉, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.广西中医药大学第一附属医院,广西中医药防治医学分子生物重点实验室,广西 南宁 530023, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1256183554904547742, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, xref=1., ext=[AuthorCompanyExt(id=1256183555210731936, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, companyId=1256183554904547742, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.The First Affiliated Hospital of Guangxi University of Chinese Medicine,Guangxi Key Laboratory of Molecular Biology of Preventive Medicine of Traditional Chinese Medicine,Nanning 530023,Guangxi,China), AuthorCompanyExt(id=1256183555386892707, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, companyId=1256183554904547742, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.广西中医药大学第一附属医院,广西中医药防治医学分子生物重点实验室,广西 南宁 530023)])])], keywords=[Keyword(id=1256183568762528328, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, language=EN, orderNo=1, keyword=chronic kidney disease), Keyword(id=1256183569618166354, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, language=EN, orderNo=2, keyword=Sanqi(Notoginseng Radix et Rhizoma)), Keyword(id=1256183570398306911, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, language=EN, orderNo=3, keyword=renal fibrosis), Keyword(id=1256183571711124076, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, language=EN, orderNo=4, keyword=mitochondrial energy metabolism), Keyword(id=1256183572805837435, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, language=EN, orderNo=5, keyword=metabolomics), Keyword(id=1256183573644698243, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, language=CN, orderNo=1, keyword=慢性肾脏病), Keyword(id=1256183574194152079, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, language=CN, orderNo=2, keyword=三七), Keyword(id=1256183574923960986, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, language=CN, orderNo=3, keyword=肾纤维化), Keyword(id=1256183575330808482, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, language=CN, orderNo=4, keyword=线粒体能量代谢), Keyword(id=1256183575888650921, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, language=CN, orderNo=5, keyword=代谢组学)], refs=[Reference(id=1256183590291891040, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, doi=null, pmid=null, pmcid=null, year=2017, volume=2, issue=2, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=NEUEN B L, CHADBAN S J, DEMAIO A R, journalName=BMJGlob Health, refType=null, unstructuredReference=NEUEN B L,CHADBAN S J,DEMAIO A R,et al. Chronic kidney disease and the global NCDs agenda[J]. BMJGlob Health20172(2):e000380., articleTitle=Chronic kidney disease and the global NCDs agenda, refAbstract=null), Reference(id=1256183590539354977, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, doi=null, pmid=null, pmcid=null, year=2020, volume=35, issue=10, pageStart=1801, pageEnd=1810, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=LI P K, GARCIA-GARCIA G, LUI S F, journalName=Pediatr Nephrol, refType=null, unstructuredReference=LI P K,GARCIA-GARCIA G,LUI S F,et al. Kidney health for everyone everywhere-from prevention to detection and equitable access to care[J]. Pediatr Nephrol202035(10):1801-1810., articleTitle=Kidney health for everyone everywhere-from prevention to detection and equitable access to care, refAbstract=null), Reference(id=1256183590803596130, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, doi=null, pmid=null, pmcid=null, year=2023, volume=324, issue=6, pageStart=F571, pageEnd=F580, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=LUTHER T, BÜLOW-ANDERBERG S, PERSSON P, journalName=Am JPhysiol Renal Physiol, refType=null, unstructuredReference=LUTHER T,BÜLOW-ANDERBERG S,PERSSON P,et al. Renal mitochondrial dysfunction in ovine experimental sepsis-associated acute kidney injury[J]. Am JPhysiol Renal Physiol2023324(6):F571-F580., articleTitle=Renal mitochondrial dysfunction in ovine experimental sepsis-associated acute kidney injury, refAbstract=null), Reference(id=1256183590975562595, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, doi=null, pmid=null, pmcid=null, year=2019, volume=95, issue=6, pageStart=1389, pageEnd=1404, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=BAIM, CHEN H, DING D, journalName=Kidney Int, refType=null, unstructuredReference=BAIM,CHEN H,DING D,et al. MicroRNA-214 promotes chronic kidney disease by disrupting mitochondrial oxidative phosphorylation[J]. Kidney Int201995(6):1389-1404., articleTitle=MicroRNA-214 promotes chronic kidney disease by disrupting mitochondrial oxidative phosphorylation, refAbstract=null), Reference(id=1256183591072031588, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, doi=null, pmid=null, pmcid=null, year=2019, volume=20, issue=5, pageStart=379, pageEnd=382, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=黄志敏, 黄仁发, 唐宇, journalName=中国中西医结合肾病杂志, refType=null, unstructuredReference=黄志敏,黄仁发,唐宇,. 基于JAK/STAT信号通路观察三七注射液对阿霉素诱导的肾纤维化大鼠炎症因子的影响[J]. 中国中西医结合肾病杂志201920(5):379-382., articleTitle=基于JAK/STAT信号通路观察三七注射液对阿霉素诱导的肾纤维化大鼠炎症因子的影响, refAbstract=null), Reference(id=1256183591155917669, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, doi=null, pmid=null, pmcid=null, year=2021, volume=39, issue=9, pageStart=156, pageEnd=159, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=黄志敏, 黄仁发, 唐宇, journalName=中华中医药学刊, refType=null, unstructuredReference=黄志敏,黄仁发,唐宇,. 基于肠肾轴理论探讨三七注射液对慢性肾脏病大鼠肠黏膜功能和肠道菌群的影响[J]. 中华中医药学刊202139(9):156-159., articleTitle=基于肠肾轴理论探讨三七注射液对慢性肾脏病大鼠肠黏膜功能和肠道菌群的影响, refAbstract=null), Reference(id=1256183591319495526, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, doi=null, pmid=null, pmcid=null, year=2021, volume=39, issue=5, pageStart=175, pageEnd=178, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=黄志敏, 黄仁发, 唐宇, journalName=中华中医药学刊, refType=null, unstructuredReference=黄志敏,黄仁发,唐宇,. 三七注射液对阿霉素肾纤维化大鼠炎症启动因子和终止因子的影响[J]. 中华中医药学刊202139(5):175-178., articleTitle=三七注射液对阿霉素肾纤维化大鼠炎症启动因子和终止因子的影响, refAbstract=null), Reference(id=1256183591390798695, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, doi=null, pmid=null, pmcid=null, year=2010, volume=8, issue=2, pageStart=188, pageEnd=1903, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=赵玲, 魏海峰, 李雅莉, journalName=中西医结合心脑血管病杂志, refType=null, unstructuredReference=赵玲,魏海峰,李雅莉,. 从血液流变学的改变分析肾上腺素致血瘀证大鼠模型的建立[J]. 中西医结合心脑血管病杂志20108(2):188-1903., articleTitle=从血液流变学的改变分析肾上腺素致血瘀证大鼠模型的建立, refAbstract=null), Reference(id=1256183591474684776, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, doi=null, pmid=null, pmcid=null, year=2020, volume=16, issue=9, pageStart=509, pageEnd=524, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=DWYER KM, KISHORE BK, ROBSON SC, journalName=Nat Rev Nephrol, refType=null, unstructuredReference=DWYER KM,KISHORE BK,ROBSON SC. Conversion of extracellular ATP into adenosine:amaster switch in renal health and disease[J]. Nat Rev Nephrol202016(9):509-524., articleTitle=Conversion of extracellular ATP into adenosine:amaster switch in renal health and disease, refAbstract=null), Reference(id=1256183591608902505, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, doi=null, pmid=null, pmcid=null, year=2017, volume=119, issue=4, pageStart=392, pageEnd=399, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=HUIY, LU M, HAN Y, el at, journalName=Acta Histochem, refType=null, unstructuredReference=HUIY,LU M,HAN Y,el at. Resveratrol improvesmitochondrial function in the remnant kidney from 5/6 nephrectomized rats[J]. Acta Histochem2017119(4):392-399., articleTitle=Resveratrol improvesmitochondrial function in the remnant kidney from 5/6 nephrectomized rats, refAbstract=null), Reference(id=1256183591734731626, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, doi=null, pmid=null, pmcid=null, year=2019, volume=14, issue=12, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=AKHTAR S, SIRAGY H M, journalName=PLoSONE, refType=null, unstructuredReference=AKHTAR S,SIRAGY H M. Pro-renin receptor suppressesmitochondrial biogenesis and function via AMPK/SIRT-1/PGC-1alpha pathway in diabetic kidney[J]. PLoSONE201914(12):e225728., articleTitle=Pro-renin receptor suppressesmitochondrial biogenesis and function via AMPK/SIRT-1/PGC-1alpha pathway in diabetic kidney, refAbstract=null), Reference(id=1256183591839589227, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, doi=null, pmid=null, pmcid=null, year=2019, volume=4, issue=23, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=BHATIA D, CHUNG K P, NAKAHIRA K, journalName=JCI Insight, refType=null, unstructuredReference=BHATIA D,CHUNG K P,NAKAHIRA K,et al. Mitophagy-dependentmacrophage reprogramming protects against kidney fibrosis[J]. JCI Insight20194(23):e132826., articleTitle=Mitophagy-dependentmacrophage reprogramming protects against kidney fibrosis, refAbstract=null), Reference(id=1256183591923475308, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, doi=null, pmid=null, pmcid=null, year=2020, volume=83, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=WANG D T, YANG Y J, ZOU X H, journalName=JNutr Biochem, refType=null, unstructuredReference=WANG D T,YANG Y J,ZOU X H,et al. Curcumin ameliorates CKD-induced mitochondrial dysfunction and oxidative stress through inhibiting GSK-3βactivity[J]. JNutr Biochem202083:108404., articleTitle=Curcumin ameliorates CKD-induced mitochondrial dysfunction and oxidative stress through inhibiting GSK-3βactivity, refAbstract=null), Reference(id=1256183592066081645, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, doi=null, pmid=null, pmcid=null, year=2020, volume=13, issue=2, pageStart=176, pageEnd=178, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=杨倩春, 李思宁, 陈硕, journalName=临床合理用药杂志, refType=null, unstructuredReference=杨倩春,李思宁,陈硕,. 代谢组学的运用及其研究进展[J]. 临床合理用药杂志202013(2):176-178., articleTitle=代谢组学的运用及其研究进展, refAbstract=null), Reference(id=1256183592158356334, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, doi=null, pmid=null, pmcid=null, year=2023, volume=16, issue=9, pageStart=1521, pageEnd=1533, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=BRILLAND B, BOUD'HORSC, WACRENIER S, journalName=Clin Kidney J, refType=null, unstructuredReference=BRILLAND B,BOUD'HORSC,WACRENIER S,etal. Kidney injury molecule1(KIM-1):a potential biomarker of acute kidney injury and tubulointerstitial injury in patientswith ANCA-glomerulonephritis[J]. Clin Kidney J202316(9):1521-1533., articleTitle=Kidney injury molecule1(KIM-1):a potential biomarker of acute kidney injury and tubulointerstitial injury in patientswith ANCA-glomerulonephritis, refAbstract=null), Reference(id=1256183592242242415, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, doi=null, pmid=null, pmcid=null, year=2023, volume=24, issue=13, pageStart=10470, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=ROMEJKO K, MARKOWSKA M, NIEMCZYK S, journalName=Int JMol Sci, refType=null, unstructuredReference=ROMEJKO K,MARKOWSKA M,NIEMCZYK S. The review of current knowledge on neutrophil gelatinase-associated lipocalin(NGAL)[J]. Int JMol Sci202324(13):10470., articleTitle=The review of current knowledge on neutrophil gelatinase-associated lipocalin(NGAL), refAbstract=null), Reference(id=1256183592330322800, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, doi=null, pmid=null, pmcid=null, year=2022, volume=153, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=MA R Y, HE Y H, FANGQ, journalName=Biomed Pharmacother, refType=null, unstructuredReference=MA R Y,HE Y H,FANGQ,etal. Ferulic acid ameliorates renal injury via improving autophagy to inhibit inflammation in diabetic nephropathymice[J]. Biomed Pharmacother2022153:113424., articleTitle=Ferulic acid ameliorates renal injury via improving autophagy to inhibit inflammation in diabetic nephropathymice, refAbstract=null), Reference(id=1256183592502289265, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, doi=null, pmid=null, pmcid=null, year=2019, volume=9, issue=19, pageStart=32, pageEnd=35, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=陈璐, journalName=中国医药科学, refType=null, unstructuredReference=陈璐. 阿魏酸钠联合厄贝沙坦对慢性肾功能衰竭患者血清炎性因子、Hcy、PTH及β2-MG的影响[J]. 中国医药科学20199(19):32-35., articleTitle=阿魏酸钠联合厄贝沙坦对慢性肾功能衰竭患者血清炎性因子、Hcy、PTH及β2-MG的影响, refAbstract=null), Reference(id=1256183592569398130, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, doi=null, pmid=null, pmcid=null, year=2018, volume=56, issue=null, pageStart=156, pageEnd=167, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=SINGH M P, CHAUHAN A K, KANG S C, journalName=Int Immunopharmacol, refType=null, unstructuredReference=SINGH M P,CHAUHAN A K,KANG S C. Morin hydrate ameliorates cisplatin-induced ER stress,inflammation and autophagy in HEK-293 cells and mice kidney via PARP-1 regulation[J]. Int Immunopharmacol201856:156-167., articleTitle=Morin hydrate ameliorates cisplatin-induced ER stress,inflammation and autophagy in HEK-293 cells and mice kidney via PARP-1 regulation, refAbstract=null), Reference(id=1256183592636506995, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, doi=null, pmid=null, pmcid=null, year=2021, volume=90, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=SINGH M P, SHARMA C, CHU S, journalName=Int Immuno-pharmacol, refType=null, unstructuredReference=SINGH M P,SHARMA C,CHU S. KANGMorin hydrate attenuates adenine-induced renal fibrosis via targeting cathepsin D signaling[J]. Int Immuno-pharmacol202190:107234., articleTitle=KANGMorin hydrate attenuates adenine-induced renal fibrosis via targeting cathepsin D signaling, refAbstract=null), Reference(id=1256183592745558900, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, doi=null, pmid=null, pmcid=null, year=2015, volume=30, issue=9, pageStart=1537, pageEnd=1540, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=VANLEDE K, KLUIJTMANS L A J, MONNENS L, journalName=Pediatr Nephrol, refType=null, unstructuredReference=VANLEDE K,KLUIJTMANS L A J,MONNENS L,et al. Urinary excretion of polyols and sugars in children with chronic kidney disease[J]. Pediatr Nephrol201530(9):1537-1540., articleTitle=Urinary excretion of polyols and sugars in children with chronic kidney disease, refAbstract=null), Reference(id=1256183592825250677, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, doi=null, pmid=null, pmcid=null, year=2020, volume=2020, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=ZHANG H, ZUO JJ, DONG SS, journalName=Journal of diabetes research, refType=null, unstructuredReference=ZHANG H,ZUO JJ,DONG SS,etal. Identification of potential serum metabolic biomarkers of diabetic kidney disease:a widely targeted metabolomics study[J]. Journal of diabetes research20202020:3049098., articleTitle=Identification of potential serum metabolic biomarkers of diabetic kidney disease:a widely targeted metabolomics study, refAbstract=null), Reference(id=1256183592942691190, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, doi=null, pmid=null, pmcid=null, year=2012, volume=53, issue=2, pageStart=117, pageEnd=124, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=SZMIT S, JANK M, MACIEJEWSKIH, journalName=Int Heart J, refType=null, unstructuredReference=SZMIT S,JANK M,MACIEJEWSKIH,et al. White blood cell transcriptome correlates with renal function in acute heart failure[J]. Int Heart J201253(2):117-124., articleTitle=White blood cell transcriptome correlates with renal function in acute heart failure, refAbstract=null), Reference(id=1256183593060131703, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, doi=null, pmid=null, pmcid=null, year=2019, volume=1165, issue=null, pageStart=325, pageEnd=346, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=SHRESTHA A, CHE R, ZHANG A, journalName=Adv Exp Med Biol, refType=null, unstructuredReference=SHRESTHA A,CHE R,ZHANG A. Role of aldosterone in renal fibrosis[J]. Adv Exp Med Biol20191165:325-346., articleTitle=Role of aldosterone in renal fibrosis, refAbstract=null), Reference(id=1256183593194349432, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, doi=null, pmid=null, pmcid=null, year=2020, volume=21, issue=13, pageStart=4679, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=BALHORN R, HARTMANN C, SCHUPP N, journalName=Int JMol Sci, refType=null, unstructuredReference=BALHORN R,HARTMANN C,SCHUPP N. Aldosterone induces DNA damage and activation of Nrf2 mainly in tubuli ofmouse kidneys[J]. Int JMol Sci202021(13):4679., articleTitle=Aldosterone induces DNA damage and activation of Nrf2 mainly in tubuli ofmouse kidneys, refAbstract=null), Reference(id=1256183593274041210, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, doi=null, pmid=null, pmcid=null, year=2011, volume=178, issue=5, pageStart=2020, pageEnd=2031, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=ZHU C, HUANG S, YUAN Y, journalName=Am JPathol, refType=null, unstructuredReference=ZHU C,HUANG S,YUAN Y,et al. Mitochondrial dysfunction mediates aldosterone-induced podocyte damage:a therapeutic target of PPARγ[J]. Am JPathol2011178(5):2020-2031., articleTitle=Mitochondrial dysfunction mediates aldosterone-induced podocyte damage:a therapeutic target of PPARγ, refAbstract=null), Reference(id=1256183593362121595, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, doi=null, pmid=null, pmcid=null, year=2020, volume=586, issue=7828, pageStart=287, pageEnd=291, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=HERNANSANZ-AGUSTÍN P, CHOYA-FOCES C, CARREGALROMERO S, journalName=Nature, refType=null, unstructuredReference=HERNANSANZ-AGUSTÍN P,CHOYA-FOCES C,CARREGALROMERO S,et al. Na+ controls hypoxic signalling by the mitochondrial respiratory chain[J]. Nature2020586(7828):287-291., articleTitle=Na+ controls hypoxic signalling by the mitochondrial respiratory chain, refAbstract=null)], funds=[Fund(id=1256183589847294813, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, awardId=81960866, language=CN, fundingSource=国家自然科学基金地区科学基金项目(81960866), fundOrder=null, country=null), Fund(id=1256183590010872670, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, awardId=zyyzdxk-2023166, language=CN, fundingSource=国家中医药管理局高水平中医药重点学科建设项目-中医内科学(zyyzdxk-2023166), fundOrder=null, country=null), Fund(id=1256183590140896095, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, awardId=桂教科研〔2022〕1号, language=CN, fundingSource=中医学广西一流学科项目(桂教科研〔2022〕1号), fundOrder=null, country=null)], companyList=[AuthorCompany(id=1256183554904547742, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, xref=1., ext=[AuthorCompanyExt(id=1256183555210731936, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, companyId=1256183554904547742, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.The First Affiliated Hospital of Guangxi University of Chinese Medicine,Guangxi Key Laboratory of Molecular Biology of Preventive Medicine of Traditional Chinese Medicine,Nanning 530023,Guangxi,China), AuthorCompanyExt(id=1256183555386892707, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, companyId=1256183554904547742, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.广西中医药大学第一附属医院,广西中医药防治医学分子生物重点实验室,广西 南宁 530023)]), AuthorCompany(id=1256183556167033266, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, xref=2., ext=[AuthorCompanyExt(id=1256183556477411766, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, companyId=1256183556167033266, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Ren'ai Branch of The First Affiliated Hospital of Guangxi University of Chinese Medicine,Nanning 530001,Guangxi,China), AuthorCompanyExt(id=1256183556531937721, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, companyId=1256183556167033266, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.广西中医药大学第一附属医院仁爱分院,广西 南宁 530001)])], figs=[ArticleFig(id=1256183576991752890, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, language=EN, label=null, caption=null, figureFileSmall=MxFdKN0kTfUa6L75zqio1w==, figureFileBig=etdBvOYz85hGFDTfTLn8+A==, tableContent=null), ArticleFig(id=1256183577457320645, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, language=CN, label=图1, caption=透射电镜下观察各组大鼠肾脏中线粒体形态, figureFileSmall=MxFdKN0kTfUa6L75zqio1w==, figureFileBig=etdBvOYz85hGFDTfTLn8+A==, tableContent=null), ArticleFig(id=1256183578426204885, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, language=EN, label=null, caption=null, figureFileSmall=C5gV9pAx0CB3/0xwwdz1nA==, figureFileBig=ZCl+4sFOmQLZbQvyxwKWeQ==, tableContent=null), ArticleFig(id=1256183579126653662, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, language=CN, label=图2, caption=各组慢性肾脏疾病大鼠样本正离子基峰图(BPC), figureFileSmall=C5gV9pAx0CB3/0xwwdz1nA==, figureFileBig=ZCl+4sFOmQLZbQvyxwKWeQ==, tableContent=null), ArticleFig(id=1256183579650941669, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, language=EN, label=null, caption=null, figureFileSmall=0ONJxTwJrfhDqixYTxsgGQ==, figureFileBig=r7psHOCKOtBl7a+CE0nFuw==, tableContent=null), ArticleFig(id=1256183580380750572, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, language=CN, label=图3, caption=各组慢性肾脏疾病大鼠样本负离子基峰图(BPC), figureFileSmall=0ONJxTwJrfhDqixYTxsgGQ==, figureFileBig=r7psHOCKOtBl7a+CE0nFuw==, tableContent=null), ArticleFig(id=1256183580833735410, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, language=EN, label=null, caption=null, figureFileSmall=Qg1PvgzHtuobXvCq1vCzDQ==, figureFileBig=trQ6g0fdPHtPf8Cc9Fe81w==, tableContent=null), ArticleFig(id=1256183581102170872, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, language=CN, label=图4, caption=各组慢性肾脏疾病大鼠尿液样本PCA得分图

注:N_Con为正常组;Model为模型组;LD为三七低剂量组;MD为三七中剂量组;HD为三七高剂量组;P_Con为阳性对照组。

, figureFileSmall=Qg1PvgzHtuobXvCq1vCzDQ==, figureFileBig=trQ6g0fdPHtPf8Cc9Fe81w==, tableContent=null), ArticleFig(id=1256183581366412029, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, language=EN, label=null, caption=null, figureFileSmall=FfJphEUWDNj3+LgTWd0Qgw==, figureFileBig=8uX7Yzrm6Y9syVwdmFEq2w==, tableContent=null), ArticleFig(id=1256183581722927875, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, language=CN, label=图5, caption=各组大鼠尿液样本负离子和正离子PLS-DA得分图

注:N_Con为正常组;Model为模型组;LD为三七低剂量组;MD为三七中剂量组;HD为三七高剂量组;P_Con为阳性对照组。

, figureFileSmall=FfJphEUWDNj3+LgTWd0Qgw==, figureFileBig=8uX7Yzrm6Y9syVwdmFEq2w==, tableContent=null), ArticleFig(id=1256183582020723465, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, language=EN, label=null, caption=null, figureFileSmall=F8UWJiuoAPsXSBzfppBByg==, figureFileBig=uEER8uxlLw87DFD1zEqdWg==, tableContent=null), ArticleFig(id=1256183582192689933, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, language=CN, label=图6, caption=各组慢性肾脏疾病大鼠比较差异代谢物火山图

注:N_Con为正常组;Model为模型组;LD为三七低剂量组;MD为三七中剂量组;HD为三七高剂量组;P_Con为阳性对照组。

, figureFileSmall=F8UWJiuoAPsXSBzfppBByg==, figureFileBig=uEER8uxlLw87DFD1zEqdWg==, tableContent=null), ArticleFig(id=1256183582448542481, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, language=EN, label=null, caption=null, figureFileSmall=0V9c5vubSYYMpc+Yd69f1w==, figureFileBig=ETIfd9MCADBeRrnTuO/iaA==, tableContent=null), ArticleFig(id=1256183582591148820, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, language=CN, label=图7, caption=各组慢性肾脏疾病大鼠差异代谢物

注:N_Con为正常组;Model为模型组;LD为三七低剂量组;MD为三七中剂量组;HD为三七高剂量组。

, figureFileSmall=0V9c5vubSYYMpc+Yd69f1w==, figureFileBig=ETIfd9MCADBeRrnTuO/iaA==, tableContent=null), ArticleFig(id=1256183582700200727, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, language=EN, label=null, caption=null, figureFileSmall=vVIl6IZfSI7hR9SJaNj1Kw==, figureFileBig=tK7AmDQUwoEis8JLMz+tbQ==, tableContent=null), ArticleFig(id=1256183582909915931, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, language=CN, label=图8, caption=三七各剂量组与模型组相比显著差异代谢物:3-Aminopentanedioate

注:N_Con为正常组;Model为模型组;LD为三七低剂量组;MD为三七中剂量组;HD为三七高剂量组。

, figureFileSmall=vVIl6IZfSI7hR9SJaNj1Kw==, figureFileBig=tK7AmDQUwoEis8JLMz+tbQ==, tableContent=null), ArticleFig(id=1256183583048327966, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, language=EN, label=null, caption=null, figureFileSmall=e3XtQBBx1ltebuircN7yWA==, figureFileBig=j+RRZfyjpUai0cMPiB1bnQ==, tableContent=null), ArticleFig(id=1256183583304180512, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, language=CN, label=图9, caption=三七各剂量组与模型组相比显著差异代谢物:4-Hydroxy-2-quinolone

注:N_Con为正常组;Model为模型组;LD为三七低剂量组;MD为三七中剂量组;HD为三七高剂量组。

, figureFileSmall=e3XtQBBx1ltebuircN7yWA==, figureFileBig=j+RRZfyjpUai0cMPiB1bnQ==, tableContent=null), ArticleFig(id=1256183583866217250, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, language=EN, label=null, caption=null, figureFileSmall=iVDhGNuUZVBl1/PuqVnBDw==, figureFileBig=jicd86PIRc9hwxuuevT0pA==, tableContent=null), ArticleFig(id=1256183583941714725, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, language=CN, label=图10, caption=三七各剂量组与模型组相比显著差异代谢物:6-Methyladenine

注:N_Con为正常组;Model为模型组;LD为三七低剂量组;MD为三七中剂量组;HD为三七高剂量组。

, figureFileSmall=iVDhGNuUZVBl1/PuqVnBDw==, figureFileBig=jicd86PIRc9hwxuuevT0pA==, tableContent=null), ArticleFig(id=1256183584126264103, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, language=EN, label=null, caption=null, figureFileSmall=/6AcaEupy8gRq7eLs9F8WQ==, figureFileBig=x33ua729luusdKcbgd43sg==, tableContent=null), ArticleFig(id=1256183584247898920, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, language=CN, label=图11, caption=三七各剂量组与模型组相比显著差异代谢物:6-Methylmercaptopurine

注:N_Con为正常对照组;Model为模型组;LD为三七低剂量组;MD为三七中剂量组;HD为三七高剂量组。

, figureFileSmall=/6AcaEupy8gRq7eLs9F8WQ==, figureFileBig=x33ua729luusdKcbgd43sg==, tableContent=null), ArticleFig(id=1256183584528917291, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, language=EN, label=null, caption=null, figureFileSmall=+or7cnVRlaWuzn8jv8Twqw==, figureFileBig=rQIeIxqVrNDN3N0YRRSypw==, tableContent=null), ArticleFig(id=1256183584633774894, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, language=CN, label=图12, caption=三七各剂量组与模型组相比显著差异代谢物:Allantoic acid

注:N_Con为正常组;Model为模型组;LD为三七低剂量组;MD为三七中剂量组;HD为三七高剂量组。

, figureFileSmall=+or7cnVRlaWuzn8jv8Twqw==, figureFileBig=rQIeIxqVrNDN3N0YRRSypw==, tableContent=null), ArticleFig(id=1256183584969319217, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, language=EN, label=null, caption=null, figureFileSmall=h/JJ9ISwPQdP/EWqw6irqQ==, figureFileBig=ZLA25LCMQFAZVBUcRa3RLg==, tableContent=null), ArticleFig(id=1256183585061593908, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, language=CN, label=图13, caption=三七各剂量组与模型组相比显著差异代谢物:Biotin

注:N_Con为正常组;Model为模型组;LD为三七低剂量组;MD为三七中剂量组;HD为三七高剂量组。

, figureFileSmall=h/JJ9ISwPQdP/EWqw6irqQ==, figureFileBig=ZLA25LCMQFAZVBUcRa3RLg==, tableContent=null), ArticleFig(id=1256183585388749623, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, language=EN, label=null, caption=null, figureFileSmall=r4Nhbf0Z5TuXSuXvNdm45w==, figureFileBig=h+fpnjS8AglKohn8A9PTYA==, tableContent=null), ArticleFig(id=1256183585481024313, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, language=CN, label=图14, caption=三七各剂量组与模型组相比显著差异代谢物:D-Arabitol

注:N_Con为正常组;Model为模型组;LD为三七低剂量组;MD为三七中剂量组;HD为三七高剂量组。

, figureFileSmall=r4Nhbf0Z5TuXSuXvNdm45w==, figureFileBig=h+fpnjS8AglKohn8A9PTYA==, tableContent=null), ArticleFig(id=1256183585787208508, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, language=EN, label=null, caption=null, figureFileSmall=dUlO194KQK4Ur1FnVaXkTw==, figureFileBig=AiW1D0LSd5Cf+7ulwnSvUQ==, tableContent=null), ArticleFig(id=1256183586215027518, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, language=CN, label=图15, caption=三七各剂量组与模型组相比显著差异代谢物:Morin

注:N_Con为正常组;Model为模型组;LD为三七低剂量组;MD为三七中剂量组;HD为三七高剂量组。

, figureFileSmall=dUlO194KQK4Ur1FnVaXkTw==, figureFileBig=AiW1D0LSd5Cf+7ulwnSvUQ==, tableContent=null), ArticleFig(id=1256183586374411074, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, language=EN, label=null, caption=null, figureFileSmall=pATdzjmEHnyuywbVkKYd4g==, figureFileBig=sVUv/HdyAdPLvsRzfHnTJA==, tableContent=null), ArticleFig(id=1256183586739315522, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, language=CN, label=图16, caption=三七各剂量组与模型组相比显著差异代谢物:Moupinamide

注:N_Con为正常组;Model为模型组;LD为三七低剂量组;MD为三七中剂量组;HD为三七高剂量组。

, figureFileSmall=pATdzjmEHnyuywbVkKYd4g==, figureFileBig=sVUv/HdyAdPLvsRzfHnTJA==, tableContent=null), ArticleFig(id=1256183587112608582, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, language=EN, label=null, caption=null, figureFileSmall=2n0zn6UbqAJH+p4WXoo/IA==, figureFileBig=qsEikxtEXzRiGl74xlDOIQ==, tableContent=null), ArticleFig(id=1256183587251020616, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, language=CN, label=图17, caption=三七各剂量组与模型组相比显著差异代谢物:trans-Ferulic acid

注:N_Con为正常组;Model为模型组;LD为三七低剂量组;MD为三七中剂量组;HD为三七高剂量组。

, figureFileSmall=2n0zn6UbqAJH+p4WXoo/IA==, figureFileBig=qsEikxtEXzRiGl74xlDOIQ==, tableContent=null), ArticleFig(id=1256183587603342155, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, language=EN, label=null, caption=null, figureFileSmall=8slIEoWKiXoFiiULi/4fEw==, figureFileBig=CHqdnrCQDi0wKt8+3OnmOg==, tableContent=null), ArticleFig(id=1256183587964052301, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, language=CN, label=图18, caption=正常组、三七各剂量组与模型组相比差异代谢物通路分析结果

注:每个点代表一个代谢通路,横坐标是富集到不同代谢通路中的Impact值,纵坐标是-log10(P)值,其中的P值是超几何分布检验的P值,P值越小,代表检测到的差异代谢物对该通路影响越显著。Impact值越大,圆点越大,该值可简单理解为贡献度,即该值越大,代表该通路下检测到的代谢物贡献度越高,对该代谢通路影响越大。颜色与P值相关,颜色越深,P值越小,颜色越浅,P值越大。

, figureFileSmall=8slIEoWKiXoFiiULi/4fEw==, figureFileBig=CHqdnrCQDi0wKt8+3OnmOg==, tableContent=null), ArticleFig(id=1256183588089881422, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, language=EN, label=null, caption=null, figureFileSmall=null, figureFileBig=null, tableContent=
组别nATPADPAMP
正常组52.136±0.1142.529±0.1254.298(0.218)
模型组50.878±0.145a6.033±0.344a11.430(1.634)a
三七低剂量组51.015±0.095a4.835±0.296ab9.272(0.735)ab
三七中剂量组51.279±0.117ab4.435±0.272ab8.287(0.120)ab
三七高剂量组51.882±0.154ab2.889±0.253ab4.707(0.347)b
阳性对照组51.896±0.176ab3.411±0.243ab5.834(0.411)ab
F/H74.017125.38127.126
P0.0000.0000.000
), ArticleFig(id=1256183588379288401, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, language=CN, label=表1, caption=

各组慢性肾脏疾病大鼠线粒体ATP、ADP、AMP含量比较分析

, figureFileSmall=null, figureFileBig=null, tableContent=
组别nATPADPAMP
正常组52.136±0.1142.529±0.1254.298(0.218)
模型组50.878±0.145a6.033±0.344a11.430(1.634)a
三七低剂量组51.015±0.095a4.835±0.296ab9.272(0.735)ab
三七中剂量组51.279±0.117ab4.435±0.272ab8.287(0.120)ab
三七高剂量组51.882±0.154ab2.889±0.253ab4.707(0.347)b
阳性对照组51.896±0.176ab3.411±0.243ab5.834(0.411)ab
F/H74.017125.38127.126
P0.0000.0000.000
), ArticleFig(id=1256183588475757394, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, language=EN, label=null, caption=null, figureFileSmall=null, figureFileBig=null, tableContent=
组别nNa+-K+-ATP酶活性Ca2+-Mg2+-ATP酶活性
正常组55.838±0.2813.314±0.092
模型组52.561±0.133a1.261±0.106a
三七低剂量组53.132±0.175ab1.682±0.138ab
三七中剂量组53.722±0.188ab2.269±0.229ab
三七高剂量组54.771±0.275ab2.679±0.238ab
阳性对照组54.649±0.379ab2.762±0.240ab
F113.65582.937
P0.0000.000
), ArticleFig(id=1256183588819690324, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, language=CN, label=表2, caption=

各组慢性肾脏疾病大鼠线粒体ATP酶活性比较分析

, figureFileSmall=null, figureFileBig=null, tableContent=
组别nNa+-K+-ATP酶活性Ca2+-Mg2+-ATP酶活性
正常组55.838±0.2813.314±0.092
模型组52.561±0.133a1.261±0.106a
三七低剂量组53.132±0.175ab1.682±0.138ab
三七中剂量组53.722±0.188ab2.269±0.229ab
三七高剂量组54.771±0.275ab2.679±0.238ab
阳性对照组54.649±0.379ab2.762±0.240ab
F113.65582.937
P0.0000.000
), ArticleFig(id=1256183588903576406, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, language=EN, label=null, caption=null, figureFileSmall=null, figureFileBig=null, tableContent=
组别n
正常组551.533±3.7979.612(0.421)12.720±1.00313.157(1.878)
模型组517.071±3.012a4.411(0.558)a3.902±0.233a5.205(1.234)a
三七低剂量组519.549±5.123a5.13(0.548)ab5.259±0.812ab5.239(1.582)a
三七中剂量组530.985±4.925ab5.47(0.459)ab7.311±1.015ab8.093(1.832)ab
三七高剂量组543.437±4.977ab7.896(3.096)b9.482±0.879ab10.702(1.811)ab
阳性对照组541.220±1.999ab7.425(3.649)b9.495±0.650ab9.640(0.287)ab
F值/χ255.64722.49278.31426.079
P0.0000.0000.0000.000
), ArticleFig(id=1256183589151040344, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, language=CN, label=表3, caption=

各组慢性肾脏疾病大鼠肾组织线粒体呼吸链复合体酶活性比较

, figureFileSmall=null, figureFileBig=null, tableContent=
组别n
正常组551.533±3.7979.612(0.421)12.720±1.00313.157(1.878)
模型组517.071±3.012a4.411(0.558)a3.902±0.233a5.205(1.234)a
三七低剂量组519.549±5.123a5.13(0.548)ab5.259±0.812ab5.239(1.582)a
三七中剂量组530.985±4.925ab5.47(0.459)ab7.311±1.015ab8.093(1.832)ab
三七高剂量组543.437±4.977ab7.896(3.096)b9.482±0.879ab10.702(1.811)ab
阳性对照组541.220±1.999ab7.425(3.649)b9.495±0.650ab9.640(0.287)ab
F值/χ255.64722.49278.31426.079
P0.0000.0000.0000.000
), ArticleFig(id=1256183589285258074, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, language=EN, label=null, caption=null, figureFileSmall=null, figureFileBig=null, tableContent=
名称mzrtP .valueVIPModelLDMDHD
N-Methyl-2-pyrrolidinone100.075 9350.60.019 31.049 8no changeno changeno changeno change
1-Aminocyclopropanecarboxylic acid102.055 2159.40.000 01.353 8downno changeupno change
2-Phenylethanol105.069 6381.90.024 22.164 8no changeno changeno changeup
Imidazole-4-acetaldehyde111.055 1121.10.012 02.388 3upno changeno changeup
Histamine112.086 774.60.011 71.105 4no changeno changeupno change
Purine120.044 2694.30.006 12.348 1upupno changeno change
Maltol127.038 5231.20.000 01.467 1no changeupno changeno change
(S)-2,3,4,5-tetrahydropyridine-2-carboxylate128.070 3341.50.000 71.234 4no changeno changeno changeno change
5-Hydroxymethylfurfuryl alcohol128.049 4673.70.034 42.835 0no changedowndowndown
Octanal129.127 2596.80.005 21.128 8downno changeno changeno change
5-Amino-2-oxopentanoic acid131.070 0199.00.027 22.152 7no changeno changeno changedown
N-Acetyl-beta-alanine132.065 0162.30.047 51.792 8upupno changeno change
1,3-Dihydro-(2H)-indol-2-one134.059 9452.40.002 31.407 2no changeupupno change
Phosphonoacetate140.070 4299.70.034 92.038 5upno changeno changeup
Valpromide144.137 9474.40.018 82.297 4no changeupno changeno change
Acetylcholine146.117 296.70.023 41.598 0upupno changeup
O-Acetylserine148.060 1159.20.030 21.583 3no changedownno changeno change
Cuminaldehyde149.095 8488.10.012 01.704 1downdownno changedown
D-Arabitol152.070 3432.70.000 21.720 7downno changedowndown
Protocatechuic acid155.106 4537.40.013 61.700 3no changedownno changeno change
Tranexamic Acid158.117 3414.60.004 51.910 3downno changedowndown
D-Alanyl-D-alanine160.096 6442.10.008 51.166 0upno changeupup
4-Hydroxy-2-quinolone161.046 8476.70.003 11.887 7upupno changeno change
N-methyl-L-glutamic Acid161.070 7502.10.032 21.247 6upno changeno changeno change
Anabasine163.038 7591.90.004 11.874 3no changedownno changeno change
Isosafrole163.075 2868.40.003 41.661 0upupupup
Enol-phenylpyruvate165.054 3310.70.003 01.845 7upno changeupup
4-Phenylbutyrate165.090 6545.70.001 81.166 5no changeupno changeno change
Epinephrine166.086 2377.70.000 21.499 5no c hangeupupup
Desaminotyrosine167.073 9164.60.032 31.352 5upupupno change
Tropate167.081 3425.30.001 71.504 5no changeupupno change
Perillic acid167.106 1617.90.002 21.505 2no changeno changedownno change
Quinolinic acid167.012 674.70.003 01.479 4no changeno changeno changeno change
Isopyridoxal168.065 1197.40.046 21.597 0no changeno changeupno change
Pyridoxamine169.097 1269.80.013 91.421 1no changeno changeno changeno change
2-Biphenylol171.076 4298.50.001 31.137 9downno changedowndown
Iminoarginine172.107 8210.50.045 41.333 9no changeno changeupno change
Swainsonine174.112 1350.00.019 21.444 0downno changeno changeno change
Formiminoglutamic acid175.071 0101.70.023 01.512 9no changeno changeno changeno change
1 H-Indole-3-acetamide175.086 4503.20.043 11.929 3downno changeno changedown
3-Methyl-L-tyrosine178.086 1325.50.006 02.552 8no changeno changeno changeup
Methyleugenolu179.106 4792.00.002 01.352 7upno changeno changeup
5-Oxo-1,2-campholide183.101 2612.80.012 31.165 2upupno changeno change
Sebacic acid185.117 5528.60.042 72.034 5upno changeno changeup
Deethylatrazine188.070 3673.50.022 02.026 3upupupup
Methyl(indol-3-yl)acetate189.078 3649.50.024 62.096 0no changeno changeno changeup
Myristicin193.085 4515.90.002 32.131 1upno changeno changeup
Methoxamine194.117 4217.60.025 62.140 0downno changeno changedown
3,4-Methylenedioxyamphetamine194.117 0313.10.002 12.791 8no changeno changeno changedown
(-)-Bornesitol194.081 0512.00.001 61.231 4upupupno change
Dopaquinone196.059 9375.30.043 01.788 0no changedowndowndown
Dethiobiotin197.127 9209.00.000 31.345 3upupupup
N-Acetylhistidine198.086 6100.40.033 51.392 9downno changeno changeno change
Spermine203.222 577.40.002 91.089 6no changeno changeno changeno change
Bufotenin205.137 2177.10.015 41.260 8no changedownno changeno change
trans-Isoasarone209.116 8490.00.014 21.417 9no changeupno changeno change
Propoxur210.112 3467.30.005 92.200 1upupupup
(+)-7-Isojasmonic acid211.132 4481.20.000 11.072 9upupupup
3-Methyl-1-(2,4,6-trihydroxyphenyl)-1-butanone211.096 0515.90.031 22.018 0no changeno changeno changeup
Apiole223.095 4570.20.005 71.875 3upupupno change
Terbutaline226.143 1651.60.007 82.487 9no changedowndowndown
Pirbuterol241.153 9128.00.000 11.774 1upno changeupno change
Ribavirin244.078 696.90.003 41.272 0upno changeno changedown
Biotin245.094 9461.30.001 71.297 4downno changeno changeno change
Osthol245.116 5716.30.000 11.671 2upno changeupno change
N-Acetyl-D-tryptophan247.128 3377.20.015 32.368 8no changeno changeno changeup
D-Octopine247.139 196.80.004 12.145 9upno changeno changeup
5-Hydroxyindoleacetylglycine249.086 4515.10.016 62.172 1no changeno changeupup
Citrinin251.090 7605.20.000 41.329 6upno changeupup
16-Oxopalmitate253.215 4705.90.002 31.894 7no changedownno changeno change
16-Hydroxy hexadecanoic acid255.230 8844.20.036 81.898 8no changeno changeno changeno change
Stearolic acid263.236 2868.10.000 82.952 8downdowndowndown
gamma-Glutamyltyramine266.120 7454.90.000 01.732 3upupupup
Nevirapine267.120 0488.90.001 21.761 9no changeupupup
Xanthoxic acid267.162 8667.40.043 11.620 8no changeno changeno changeno change
Baicalein271.179 7702.90.000 01.909 4no changeno changeupno change
(5-L-Glutamyl)-L-glutamate277.103 7131.70.000 11.341 7upupupup
Sulfamethazine279.092 6749.00.040 81.030 1no changeno changeno changeno change
Guanosine284.098 4280.30.034 01.141 6no changeno changeno changeno change
9-OxoODE295.225 6867.60.008 82.429 9upupno changeup
Enterolactone299.126 8594.60.002 11.547 7upno changeupup
Dihydrocapsaicin308.220 7626.30.000 12.735 5upupupup
Moupinamide314.123 7174.40.019 11.143 0downno changeno changeno change
N-Acetylthienamycin314.102 676.80.038 81.170 4no changeno changedownno change
Oxycodone316.154 1510.00.027 21.497 7upupupno change
Clostebol323.182 7653.50.004 41.738 5no cha ngeno changeupno change
Melibiose325.112 6322.20.015 22.389 3no cha ngeno changeno changeno change
Bitertanol338.194 7732.10.001 02.094 7no changedownno changeno change
17alpha,21-Dihydroxypregnenolone349.235 9563.20.012 01.706 2no changeno changeno changeno change
Cortisone360.202 7450.80.004 11.179 6upupupno change
Aldosterone361.220 4877.60.035 61.759 6no changeno changeno changeno change
18-Hydroxycorticosterone363.214 7546.50.023 31.170 0no changeno changeno changedown
Tangeritin373.127 5794.10.000 01.097 4downno changedowndown
S-Adenosylmethionine398.239 8792.90.016 61.347 2no changeno changeno changeno change
N1,N8-Bis(4-coumaroyl)spermidine438.240 2489.80.003 81.191 6downno changeno changedown
Creatinine112.984 7921.70.011 92.422 1no changeno changeno changeup
5-Aminopentanoic acid115.920 9813.70.017 11.614 0no changeno changedowndown
Citramalic acid129.018 8142.00.001 01.893 8downno changedowndown
Glycyl-glycine132.048 9177.90.034 71.877 3no changeno changeno changedown
Adenine134.047 4250.60.034 41.943 5no changeno changeno changeno change
3-Dehydro-L-threonate134.024 9452.70.001 31.297 0downno changedowndown
Threonic acid135.030 1118.10.043 11.451 5no changeno changeno changeno change
Dimethylbenzimidazole145.040 8431.20.005 82.076 3no changeno changeno changeno change
D-Glutamine145.062 288.50.017 81.212 3no changeno changeno changeno change
3-Aminopentanedioate146.046 094.30.000 91.252 4upno changeno changeno change
6-Methyladenine148.063 0350.20.009 51.673 5upno changeno changeup
D-Xylose149.045 793.00.015 51.286 7upno changeno changeup
(R)-Mandelamide151.060 6983.40.011 81.356 9no changedownno changeno change
3-Hydroxyvalproic acid159.102 6331.40.030 81.513 1no changeno changeno changeno change
Oxoadipic acid160.040 6454.30.022 42.288 4no changeno changeno changeup
Umbelliferone161.024 5533.10.048 62.446 7no changeno changeno changeno change
L-Phenylalanine164.071 8304.90.008 41.220 6no changeno changeno changeup
6-Methylmercaptopurine165.021 0142.50.001 01.642 3upupno changeno change
Terephthalate165.019 7388.40.022 11.642 2no changeno changeno changeup
Hydantoin-5-propionic acid171.041 495.70.018 21.498 5upno changeno changeno change
N-Acetylleucine172.098 0340.40.017 41.108 7no changeno changeno changeup
Allantoic acid175.048 382.70.000 11.035 9downno changeno changeno change
2-Dehydro-D-glucono-1,5-lactone176.035 3206.60.001 21.209 1no changedownno changeno change
D-Mannonate177.040 581.40.002 71.195 3no changedownno changeno change
4-Hydroxyphenylpyruvic acid179.035 2303.30.000 41.048 9no changeno changeno changeno change
D-Mannose179.056 490.10.012 91.120 3no changeno changeupno change
Homovanillate181.050 7164.00.021 22.061 9upupno changeno change
Hydroxyphenyllactic acid181.050 5253.80.000 02.968 4no changeupupup
2',6'-Dihydroxy-4'-methoxyacetophenone181.050 6426.90.033 61.037 9upno changeupno change
10-Oxodecanoate186.121 9459.70.003 81.003 1no changedownno changeno change
trans-Ferulic acid193.050 8296.60.000 11.614 6downdowndowndown
Galactaric acid209.030 277.50.001 71.450 4upno changeno changeno change
Milrinone210.067 1609.40.004 51.762 7no changeno changeno changeno change
Tridecanoic acid214.108 6393.80.050 02.001 8no changeno changeno changedown
N-Acetyl-D-glucosamine221.154 8855.30.010 51.773 0no changeno changeno changeno change
Aciclovir225.080 3425.40.006 01.062 3downno changedowndown
Xylitol 5-phosphate231.027 7100.40.024 81.257 3upno changeupno change
Equol241.087 2685.90.003 21.631 0no changedownno changeno change
Uridine243.061 8166.70.019 92.366 6downdownno changeno change
Pyridoxal phosphate247.028 0317.90.011 71.148 0upno changeno changeno change
Shikimate 3-phosphate253.017 8470.80.003 92.324 5no changeno changeno changedown
Palmitic acid255.233 1874.80.002 31.503 0upno changeno changeno change
Zidovudine267.090 7459.30.000 01.243 5upupupup
Norizalpinin269.045 6471.30.013 31.542 7no changeno changedownno change
3'-Hydroxydaidzein269.045 5537.30.011 11.040 4no changeno changeno changeno change
Arbutin272.095 7569.00.004 32.042 9downno changeno changedown
beta-D-3-Ribofuranosyluric acid281.053 9128.20.021 91.251 5no changeno changeno changeno change
Dihydrotestosterone289.165 9322.00.000 01.042 4upno changeupup
Kaempferide299.056 3687.90.000 11.744 2upn o changeno changeno change
Morin301.037 7369.60.036 21.052 9downno changeno changeno change
(S,E)-Zearalenone317.139 2787.70.001 72.381 2no changeno changeno changeno change
GMP344.039 7149.60.001 81.044 0no changeupno changedown
Pirenzepine350.163 4521.10.000 01.605 7upno changeupdown
Sinigrin359.033 7419.20.000 02.481 8no changeupno changeup
Deoxycholic acid392.288 1790.80.019 71.005 2no changeno changeno changeno change
Carvedilol405.189 0563.40.021 21.369 0downdownno changeno change
Allocholic acid407.281 7677.70.031 11.169 0downdowndownno change
Daidzin415.101 5491.30.040 81.823 3no changeno changeno changeno change
Astragalin448.108 5464.70.028 82.674 4no ch angeno changeno changeno change
), ArticleFig(id=1256183589583053660, tenantId=1146029695717560320, journalId=1255847919539208197, articleId=1256183395432915307, language=CN, label=表4, caption=

差异代谢物

, figureFileSmall=null, figureFileBig=null, tableContent=
名称mzrtP .valueVIPModelLDMDHD
N-Methyl-2-pyrrolidinone100.075 9350.60.019 31.049 8no changeno changeno changeno change
1-Aminocyclopropanecarboxylic acid102.055 2159.40.000 01.353 8downno changeupno change
2-Phenylethanol105.069 6381.90.024 22.164 8no changeno changeno changeup
Imidazole-4-acetaldehyde111.055 1121.10.012 02.388 3upno changeno changeup
Histamine112.086 774.60.011 71.105 4no changeno changeupno change
Purine120.044 2694.30.006 12.348 1upupno changeno change
Maltol127.038 5231.20.000 01.467 1no changeupno changeno change
(S)-2,3,4,5-tetrahydropyridine-2-carboxylate128.070 3341.50.000 71.234 4no changeno changeno changeno change
5-Hydroxymethylfurfuryl alcohol128.049 4673.70.034 42.835 0no changedowndowndown
Octanal129.127 2596.80.005 21.128 8downno changeno changeno change
5-Amino-2-oxopentanoic acid131.070 0199.00.027 22.152 7no changeno changeno changedown
N-Acetyl-beta-alanine132.065 0162.30.047 51.792 8upupno changeno change
1,3-Dihydro-(2H)-indol-2-one134.059 9452.40.002 31.407 2no changeupupno change
Phosphonoacetate140.070 4299.70.034 92.038 5upno changeno changeup
Valpromide144.137 9474.40.018 82.297 4no changeupno changeno change
Acetylcholine146.117 296.70.023 41.598 0upupno changeup
O-Acetylserine148.060 1159.20.030 21.583 3no changedownno changeno change
Cuminaldehyde149.095 8488.10.012 01.704 1downdownno changedown
D-Arabitol152.070 3432.70.000 21.720 7downno changedowndown
Protocatechuic acid155.106 4537.40.013 61.700 3no changedownno changeno change
Tranexamic Acid158.117 3414.60.004 51.910 3downno changedowndown
D-Alanyl-D-alanine160.096 6442.10.008 51.166 0upno changeupup
4-Hydroxy-2-quinolone161.046 8476.70.003 11.887 7upupno changeno change
N-methyl-L-glutamic Acid161.070 7502.10.032 21.247 6upno changeno changeno change
Anabasine163.038 7591.90.004 11.874 3no changedownno changeno change
Isosafrole163.075 2868.40.003 41.661 0upupupup
Enol-phenylpyruvate165.054 3310.70.003 01.845 7upno changeupup
4-Phenylbutyrate165.090 6545.70.001 81.166 5no changeupno changeno change
Epinephrine166.086 2377.70.000 21.499 5no c hangeupupup
Desaminotyrosine167.073 9164.60.032 31.352 5upupupno change
Tropate167.081 3425.30.001 71.504 5no changeupupno change
Perillic acid167.106 1617.90.002 21.505 2no changeno changedownno change
Quinolinic acid167.012 674.70.003 01.479 4no changeno changeno changeno change
Isopyridoxal168.065 1197.40.046 21.597 0no changeno changeupno change
Pyridoxamine169.097 1269.80.013 91.421 1no changeno changeno changeno change
2-Biphenylol171.076 4298.50.001 31.137 9downno changedowndown
Iminoarginine172.107 8210.50.045 41.333 9no changeno changeupno change
Swainsonine174.112 1350.00.019 21.444 0downno changeno changeno change
Formiminoglutamic acid175.071 0101.70.023 01.512 9no changeno changeno changeno change
1 H-Indole-3-acetamide175.086 4503.20.043 11.929 3downno changeno changedown
3-Methyl-L-tyrosine178.086 1325.50.006 02.552 8no changeno changeno changeup
Methyleugenolu179.106 4792.00.002 01.352 7upno changeno changeup
5-Oxo-1,2-campholide183.101 2612.80.012 31.165 2upupno changeno change
Sebacic acid185.117 5528.60.042 72.034 5upno changeno changeup
Deethylatrazine188.070 3673.50.022 02.026 3upupupup
Methyl(indol-3-yl)acetate189.078 3649.50.024 62.096 0no changeno changeno changeup
Myristicin193.085 4515.90.002 32.131 1upno changeno changeup
Methoxamine194.117 4217.60.025 62.140 0downno changeno changedown
3,4-Methylenedioxyamphetamine194.117 0313.10.002 12.791 8no changeno changeno changedown
(-)-Bornesitol194.081 0512.00.001 61.231 4upupupno change
Dopaquinone196.059 9375.30.043 01.788 0no changedowndowndown
Dethiobiotin197.127 9209.00.000 31.345 3upupupup
N-Acetylhistidine198.086 6100.40.033 51.392 9downno changeno changeno change
Spermine203.222 577.40.002 91.089 6no changeno changeno changeno change
Bufotenin205.137 2177.10.015 41.260 8no changedownno changeno change
trans-Isoasarone209.116 8490.00.014 21.417 9no changeupno changeno change
Propoxur210.112 3467.30.005 92.200 1upupupup
(+)-7-Isojasmonic acid211.132 4481.20.000 11.072 9upupupup
3-Methyl-1-(2,4,6-trihydroxyphenyl)-1-butanone211.096 0515.90.031 22.018 0no changeno changeno changeup
Apiole223.095 4570.20.005 71.875 3upupupno change
Terbutaline226.143 1651.60.007 82.487 9no changedowndowndown
Pirbuterol241.153 9128.00.000 11.774 1upno changeupno change
Ribavirin244.078 696.90.003 41.272 0upno changeno changedown
Biotin245.094 9461.30.001 71.297 4downno changeno changeno change
Osthol245.116 5716.30.000 11.671 2upno changeupno change
N-Acetyl-D-tryptophan247.128 3377.20.015 32.368 8no changeno changeno changeup
D-Octopine247.139 196.80.004 12.145 9upno changeno changeup
5-Hydroxyindoleacetylglycine249.086 4515.10.016 62.172 1no changeno changeupup
Citrinin251.090 7605.20.000 41.329 6upno changeupup
16-Oxopalmitate253.215 4705.90.002 31.894 7no changedownno changeno change
16-Hydroxy hexadecanoic acid255.230 8844.20.036 81.898 8no changeno changeno changeno change
Stearolic acid263.236 2868.10.000 82.952 8downdowndowndown
gamma-Glutamyltyramine266.120 7454.90.000 01.732 3upupupup
Nevirapine267.120 0488.90.001 21.761 9no changeupupup
Xanthoxic acid267.162 8667.40.043 11.620 8no changeno changeno changeno change
Baicalein271.179 7702.90.000 01.909 4no changeno changeupno change
(5-L-Glutamyl)-L-glutamate277.103 7131.70.000 11.341 7upupupup
Sulfamethazine279.092 6749.00.040 81.030 1no changeno changeno changeno change
Guanosine284.098 4280.30.034 01.141 6no changeno changeno changeno change
9-OxoODE295.225 6867.60.008 82.429 9upupno changeup
Enterolactone299.126 8594.60.002 11.547 7upno changeupup
Dihydrocapsaicin308.220 7626.30.000 12.735 5upupupup
Moupinamide314.123 7174.40.019 11.143 0downno changeno changeno change
N-Acetylthienamycin314.102 676.80.038 81.170 4no changeno changedownno change
Oxycodone316.154 1510.00.027 21.497 7upupupno change
Clostebol323.182 7653.50.004 41.738 5no cha ngeno changeupno change
Melibiose325.112 6322.20.015 22.389 3no cha ngeno changeno changeno change
Bitertanol338.194 7732.10.001 02.094 7no changedownno changeno change
17alpha,21-Dihydroxypregnenolone349.235 9563.20.012 01.706 2no changeno changeno changeno change
Cortisone360.202 7450.80.004 11.179 6upupupno change
Aldosterone361.220 4877.60.035 61.759 6no changeno changeno changeno change
18-Hydroxycorticosterone363.214 7546.50.023 31.170 0no changeno changeno changedown
Tangeritin373.127 5794.10.000 01.097 4downno changedowndown
S-Adenosylmethionine398.239 8792.90.016 61.347 2no changeno changeno changeno change
N1,N8-Bis(4-coumaroyl)spermidine438.240 2489.80.003 81.191 6downno changeno changedown
Creatinine112.984 7921.70.011 92.422 1no changeno changeno changeup
5-Aminopentanoic acid115.920 9813.70.017 11.614 0no changeno changedowndown
Citramalic acid129.018 8142.00.001 01.893 8downno changedowndown
Glycyl-glycine132.048 9177.90.034 71.877 3no changeno changeno changedown
Adenine134.047 4250.60.034 41.943 5no changeno changeno changeno change
3-Dehydro-L-threonate134.024 9452.70.001 31.297 0downno changedowndown
Threonic acid135.030 1118.10.043 11.451 5no changeno changeno changeno change
Dimethylbenzimidazole145.040 8431.20.005 82.076 3no changeno changeno changeno change
D-Glutamine145.062 288.50.017 81.212 3no changeno changeno changeno change
3-Aminopentanedioate146.046 094.30.000 91.252 4upno changeno changeno change
6-Methyladenine148.063 0350.20.009 51.673 5upno changeno changeup
D-Xylose149.045 793.00.015 51.286 7upno changeno changeup
(R)-Mandelamide151.060 6983.40.011 81.356 9no changedownno changeno change
3-Hydroxyvalproic acid159.102 6331.40.030 81.513 1no changeno changeno changeno change
Oxoadipic acid160.040 6454.30.022 42.288 4no changeno changeno changeup
Umbelliferone161.024 5533.10.048 62.446 7no changeno changeno changeno change
L-Phenylalanine164.071 8304.90.008 41.220 6no changeno changeno changeup
6-Methylmercaptopurine165.021 0142.50.001 01.642 3upupno changeno change
Terephthalate165.019 7388.40.022 11.642 2no changeno changeno changeup
Hydantoin-5-propionic acid171.041 495.70.018 21.498 5upno changeno changeno change
N-Acetylleucine172.098 0340.40.017 41.108 7no changeno changeno changeup
Allantoic acid175.048 382.70.000 11.035 9downno changeno changeno change
2-Dehydro-D-glucono-1,5-lactone176.035 3206.60.001 21.209 1no changedownno changeno change
D-Mannonate177.040 581.40.002 71.195 3no changedownno changeno change
4-Hydroxyphenylpyruvic acid179.035 2303.30.000 41.048 9no changeno changeno changeno change
D-Mannose179.056 490.10.012 91.120 3no changeno changeupno change
Homovanillate181.050 7164.00.021 22.061 9upupno changeno change
Hydroxyphenyllactic acid181.050 5253.80.000 02.968 4no changeupupup
2',6'-Dihydroxy-4'-methoxyacetophenone181.050 6426.90.033 61.037 9upno changeupno change
10-Oxodecanoate186.121 9459.70.003 81.003 1no changedownno changeno change
trans-Ferulic acid193.050 8296.60.000 11.614 6downdowndowndown
Galactaric acid209.030 277.50.001 71.450 4upno changeno changeno change
Milrinone210.067 1609.40.004 51.762 7no changeno changeno changeno change
Tridecanoic acid214.108 6393.80.050 02.001 8no changeno changeno changedown
N-Acetyl-D-glucosamine221.154 8855.30.010 51.773 0no changeno changeno changeno change
Aciclovir225.080 3425.40.006 01.062 3downno changedowndown
Xylitol 5-phosphate231.027 7100.40.024 81.257 3upno changeupno change
Equol241.087 2685.90.003 21.631 0no changedownno changeno change
Uridine243.061 8166.70.019 92.366 6downdownno changeno change
Pyridoxal phosphate247.028 0317.90.011 71.148 0upno changeno changeno change
Shikimate 3-phosphate253.017 8470.80.003 92.324 5no changeno changeno changedown
Palmitic acid255.233 1874.80.002 31.503 0upno changeno changeno change
Zidovudine267.090 7459.30.000 01.243 5upupupup
Norizalpinin269.045 6471.30.013 31.542 7no changeno changedownno change
3'-Hydroxydaidzein269.045 5537.30.011 11.040 4no changeno changeno changeno change
Arbutin272.095 7569.00.004 32.042 9downno changeno changedown
beta-D-3-Ribofuranosyluric acid281.053 9128.20.021 91.251 5no changeno changeno changeno change
Dihydrotestosterone289.165 9322.00.000 01.042 4upno changeupup
Kaempferide299.056 3687.90.000 11.744 2upn o changeno changeno change
Morin301.037 7369.60.036 21.052 9downno changeno changeno change
(S,E)-Zearalenone317.139 2787.70.001 72.381 2no changeno changeno changeno change
GMP344.039 7149.60.001 81.044 0no changeupno changedown
Pirenzepine350.163 4521.10.000 01.605 7upno changeupdown
Sinigrin359.033 7419.20.000 02.481 8no changeupno changeup
Deoxycholic acid392.288 1790.80.019 71.005 2no changeno changeno changeno change
Carvedilol405.189 0563.40.021 21.369 0downdownno changeno change
Allocholic acid407.281 7677.70.031 11.169 0downdowndownno change
Daidzin415.101 5491.30.040 81.823 3no changeno changeno changeno change
Astragalin448.108 5464.70.028 82.674 4no ch angeno changeno changeno change
)], attaches=null, journal=Journal(id=1255846881855815682, delFlag=0, nameCn=中华中医药学刊, nameEn=Chinese Archives of Traditional Chinese Medicine, nameHistory1=null, nameHistory2=null, issn=1673-7717, eissn=null, cn=21-1546/R, coden=null, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=v4T+dd+NLAnioIpGAbkcEQ==, journalPrice=null, startedYear=null, abbrevIsoEn=Chinese Archives of Traditional Chinese Medicine, journalRemark=null, publicationField=null, createdTime=1777346829146, updatedTime=1777347949387, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=C, firstLetterEn=C, subjectCode=Life Sciences, subjectName=null, subjectCodeEn=Life Sciences, subjectNameEn=null, picCn=v4T+dd+NLAnioIpGAbkcEQ==, picEn=RAy5vuC40hwJB+Y0pEARug==, jcr=null, cjcr=null, exts=[JournalExt(id=1255851580587368789, language=CN, name=中华中医药学刊, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1777347949406, updatedTime=1777347949406, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=https://zyhs.cbpt.cnki.net/index.aspx?t=1, submissionEditorUrl=https://zyhs.cbpt.cnki.net/index.aspx?t=3, submissionReviewUrl=https://zyhs.cbpt.cnki.net/index.aspx?t=2, submissionCeEditorUrl=, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1255851580641894742, language=EN, name=Chinese Archives of Traditional Chinese Medicine, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1777347949419, updatedTime=1777347949419, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=https://zyhs.cbpt.cnki.net/index.aspx?t=1, submissionEditorUrl=https://zyhs.cbpt.cnki.net/index.aspx?t=3, submissionReviewUrl=https://zyhs.cbpt.cnki.net/index.aspx?t=2, submissionCeEditorUrl=, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1255847919539208197, websiteList=[Website(id=1255847989868900719, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1255847919539208197, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/zhzyyxk/CN, language=CN, createTime=1777347093312, createBy=18614031015, updateTime=1777347427646, updateBy=18614031015, name=中华中医药学刊-中文, tplId=1146099689490845704, title=中华中医药学刊, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1255849512594170105, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1255847989868900719, code=articleTextType, value=kx, createTime=1777347456358, updateTime=1777347456358, creator=18614031015, updator=18614031015), WebsiteProps(id=1255849512564809974, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1255847989868900719, code=banner, value=null, createTime=1777347456352, updateTime=1777347456352, creator=18614031015, updator=18614031015), WebsiteProps(id=1255849512631918844, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1255847989868900719, code=grayFlag, value=0, createTime=1777347456367, updateTime=1777347456367, creator=18614031015, updator=18614031015), WebsiteProps(id=1255849512552227061, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1255847989868900719, code=logo, value=https://castjournals.cast.org.cn/joweb/zhzyyxk/CN/file/pic?fileId=uitCA2DBwhJaQSiSV07uhw==, createTime=1777347456348, updateTime=1777347456348, creator=18614031015, updator=18614031015), WebsiteProps(id=1255849512657084670, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1255847989868900719, code=minRunFlag, value=0, createTime=1777347456373, updateTime=1777347456373, creator=18614031015, updator=18614031015), WebsiteProps(id=1255849512589975800, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1255847989868900719, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/zhzyyxk/CN/file/pic, createTime=1777347456357, updateTime=1777347456357, creator=18614031015, updator=18614031015), WebsiteProps(id=1255849512648696061, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1255847989868900719, code=silenceFlag, value=0, createTime=1777347456371, updateTime=1777347456371, creator=18614031015, updator=18614031015), WebsiteProps(id=1255849512581587191, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1255847989868900719, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1777347456355, updateTime=1777347456355, creator=18614031015, updator=18614031015), WebsiteProps(id=1255849512619335930, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1255847989868900719, code=themeColor, value=null, createTime=1777347456364, updateTime=1777347456364, creator=18614031015, updator=18614031015), WebsiteProps(id=1255849512627724539, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1255847989868900719, code=themeStyle, value=null, createTime=1777347456366, updateTime=1777347456366, creator=18614031015, updator=18614031015)]), Website(id=1255847989944398211, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1255847919539208197, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/zhzyyxk/EN, language=EN, createTime=1777347093330, createBy=18614031015, updateTime=1777347417860, updateBy=18614031015, name=中华中医药学刊-英文, tplId=1146101810881728533, title=Chinese Archives of Traditional Chinese Medicine, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1255849538993119491, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1255847989944398211, code=articleTextType, value=kx, createTime=1777347462652, updateTime=1777347462652, creator=18614031015, updator=18614031015), WebsiteProps(id=1255849538972147968, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1255847989944398211, code=banner, value=null, createTime=1777347462647, updateTime=1777347462647, creator=18614031015, updator=18614031015), WebsiteProps(id=1255849539047645446, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1255847989944398211, code=grayFlag, value=0, createTime=1777347462665, updateTime=1777347462665, creator=18614031015, updator=18614031015), WebsiteProps(id=1255849538930204927, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1255847989944398211, code=logo, value=https://castjournals.cast.org.cn/joweb/zhzyyxk/EN/file/pic?fileId=uitCA2DBwhJaQSiSV07uhw==, createTime=1777347462637, updateTime=1777347462637, creator=18614031015, updator=18614031015), WebsiteProps(id=1255849539064422664, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1255847989944398211, code=minRunFlag, value=0, createTime=1777347462669, updateTime=1777347462669, creator=18614031015, updator=18614031015), WebsiteProps(id=1255849538988925186, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1255847989944398211, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/zhzyyxk/EN/file/pic, createTime=1777347462651, updateTime=1777347462651, creator=18614031015, updator=18614031015), WebsiteProps(id=1255849539060228359, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1255847989944398211, code=silenceFlag, value=0, createTime=1777347462668, updateTime=1777347462668, creator=18614031015, updator=18614031015), WebsiteProps(id=1255849538980536577, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1255847989944398211, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1777347462649, updateTime=1777347462649, creator=18614031015, updator=18614031015), WebsiteProps(id=1255849539001508100, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1255847989944398211, code=themeColor, value=null, createTime=1777347462654, updateTime=1777347462654, creator=18614031015, updator=18614031015), WebsiteProps(id=1255849539039256837, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1255847989944398211, code=themeStyle, value=null, createTime=1777347462663, updateTime=1777347462663, creator=18614031015, updator=18614031015)])], journalTitle=中华中医药学刊, weixinUrl=null, journalUrl=https://castjournals.cast.org.cn/zhzyyxk, iacademicId=null, status=1, seqNo=null, journalTitleEn=Chinese Archives of Traditional Chinese Medicine, journalPhotoCn=v4T+dd+NLAnioIpGAbkcEQ==, journalPhotoEn=RAy5vuC40hwJB+Y0pEARug==, journalFirstLetter=C, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false), detailUrlCn=https://castjournals.cast.org.cn/joweb/zhzyyxk/CN/10.13193/j.issn.1673-7717.2025.12.008, detailUrlEn=https://castjournals.cast.org.cn/joweb/zhzyyxk/EN/10.13193/j.issn.1673-7717.2025.12.008, pdfUrlCn=https://castjournals.cast.org.cn/joweb/zhzyyxk/CN/PDF/10.13193/j.issn.1673-7717.2025.12.008, pdfUrlEn=https://castjournals.cast.org.cn/joweb/zhzyyxk/EN/PDF/10.13193/j.issn.1673-7717.2025.12.008, aliStartDate=null, aliEndDate=null, collectionFlag=false, citedCount=null, citedUrl=null, reference=null)
收藏切换
基于代谢组学探讨三七对肾纤维化大鼠线粒体能量代谢的影响
收藏切换
PDF下载
黄志敏 1 , 陆良喜 2 , 吴金玉 1
中华中医药学刊 | 国家项目点击 2025,43(12): 47-54
收起
收藏切换
中华中医药学刊 | 国家项目点击 2025, 43(12): 47-54
基于代谢组学探讨三七对肾纤维化大鼠线粒体能量代谢的影响
全屏
黄志敏1, 陆良喜2, 吴金玉1
作者信息
  • 1.广西中医药大学第一附属医院,广西中医药防治医学分子生物重点实验室,广西 南宁 530023
  • 2.广西中医药大学第一附属医院仁爱分院,广西 南宁 530001
  • 黄志敏(1988-),女,广西贵港人,主治医师,博士,研究方向:中医药防治风湿免疫疾病。

通讯作者:

吴金玉(1965-),女,广东广州人,教授、主任医师,博士研究生导师,博士,研究方向:中医药防治风湿免疫疾病。E-mail:
Investigating Effect of Sanqi(Notoginseng Radix et Rhizoma)on Mitochondrial Energy Metabolism in Rats with Renal Fibrosis Based on Metabolomics
Zhimin HUANG1, Liangxi LU2, Jinyu WU1
Affiliations
  • 1.The First Affiliated Hospital of Guangxi University of Chinese Medicine,Guangxi Key Laboratory of Molecular Biology of Preventive Medicine of Traditional Chinese Medicine,Nanning 530023,Guangxi,China
  • 2.Ren'ai Branch of The First Affiliated Hospital of Guangxi University of Chinese Medicine,Nanning 530001,Guangxi,China
出版时间: 2025-12-10 doi: 10.13193/j.issn.1673-7717.2025.12.008
文章导航
收藏切换
目的

研究三七对血瘀证阿霉素肾纤维化大鼠线粒体能量代谢的影响。

方法

将30只SD大鼠随机分为6组:正常组、模型组、三七低剂量组、三七中剂量组、三七高剂量组、阳性对照组,每组5只。采用电镜观察大鼠肾组织线粒体结构,化学法检测肾组织三磷酸腺苷(Adenosine triphosphate,ATP)、二磷酸腺苷(Adenosine diphosphate,ADP)、一磷酸腺苷(Adenosinemonophosphate,AMP)含量、Na+-K+-ATP酶、Ca2+-Mg2+-ATP酶活性、线粒体呼吸链复合体酶Ⅰ~Ⅳ活性。采用液相色谱仪、质谱仪对尿液进行代谢物成分分析,获得代谢差异物后,进行KEGG代谢通路富集。

结果

电镜下可见模型组大鼠肾组织线粒体结构不完整,三七可以维持肾组织线粒体结构稳态。三七可以提高肾组织线粒体ATP含量、Na+-K+-ATP酶、Ca2+-Mg2+-ATP酶、线粒体呼吸链复合体酶Ⅰ、Ⅱ、Ⅲ、Ⅳ活性;降低肾组织线粒体ADP、AMP含量。进行三七低、中、高剂量组、模型组和正常组分析对比,筛查出11个差异尿液代谢产物,分别为Ferulic acid、Morin、Arabitol、Acetamide、Biotin、Allantoic acid、6-Methylmercaptopurine、4-Hydroxy-2-quinolone、Aminopentanedioate、6-Methyladenine、Moupinamide。进一步对各实验组动物尿液代谢物KEGG通路富集分析结果显示:醛固酮调控的钠重吸收通路差异具有显著统计学意义。

结论

三七通过调节差异尿液代谢产物的代谢,调控醛固酮调节Na+重吸收通路,从多靶点、多途径改善血瘀证慢性肾脏疾病(Chronic Kidney Diseases,CKD)大鼠的线粒体能量代谢,发挥抗肾纤维化作用。

慢性肾脏病  /  三七  /  肾纤维化  /  线粒体能量代谢  /  代谢组学
Objective

To study the effectof Sanqi(Notoginseng Radix et Rhizoma)onmitochondrial energy metabolism of rats with adriamycin induced kidney fibrosis with blood stasis.

Methods

Thirty rats were divided into 6 groups random ly,including normal group,model group,Sanqi(Notoginseng Radix et Rhizoma)low-dose group,Sanqi(Notoginseng Radix et Rhizoma)medium-dose group,Sanqi(Notoginseng Radix et Rhizoma)high-dose group and positive control group,with 5 rats in each group.Themitochondrial structure of rat renal tissue was observed by electron microscopy.The contents of adenosine triphosphate(ATP),adenosine diphosphate(ADP),adenosine monophosphate(AMP),the activities of Na+ -K+ -ATPase,Ca2+ -Mg2+-ATPase and the activities ofmitochondrial respiratory chain complex enzymeⅠ-Ⅳwere detected by chemical method.The metabolites of urine were analyzed by liquid chromatograph and mass spectrometer.The differential metabolites were enriched by Kyoto Encyclopedia of Genes and Genomes(KEGG)metabolic pathway.

Results

Under electron microscope,the mitochondrial structure of renal tissue in the model group was incomplete,and Sanqi(Notoginseng Radix et Rhizoma)could maintain the homeostasis of renalmitochondrial structure.Sanqi(Notoginseng Radix et Rhizoma)could increase the mitochondrial ATP contentof the renal tissue,the activities of Na+-K+-ATPase,Ca2+-Mg2+-ATPase andmitochondrial respiratory chain complex enzymeⅠ-Ⅳ.Sanqi(Notoginseng Radix et Rhizoma)could reduce the contents of mitochondrial ADP and AMP of renal tissue.After analysis and comparison among the groups,11 different urine metabolites were screened,including ferulic acid,forin,arabitol,acetamide,biotin,allantoic acid,6-methylmercaptopurine,4-hydroxy-2-quinolone,aminopentanedioate,6-methyladenine and moupinamide.Further enrichment of urinemetabolites by KEGG in different experimental groups showed that the aldosterone-regulated sodium reabsorption signal pathway was significantly different.

Conclusion

Sanqi(Notoginseng Radix et Rhizoma)regulates the differential urine metabolites and raldosterone-regulated sodium reabsorption signal pathway.Sanqi(Notoginseng Radix et Rhizoma)can improve mitochondrial energy metabolism and renal fibrosis in chronic kidney diseases(CKD)rats with blood stasis bymulti-target and multi-pathway.

chronic kidney disease  /  Sanqi(Notoginseng Radix et Rhizoma)  /  renal fibrosis  /  mitochondrial energy metabolism  /  metabolomics
黄志敏, 陆良喜, 吴金玉. 基于代谢组学探讨三七对肾纤维化大鼠线粒体能量代谢的影响. 中华中医药学刊, 2025 , 43 (12) : 47 -54 . DOI: 10.13193/j.issn.1673-7717.2025.12.008
Zhimin HUANG, Liangxi LU, Jinyu WU. Investigating Effect of Sanqi(Notoginseng Radix et Rhizoma)on Mitochondrial Energy Metabolism in Rats with Renal Fibrosis Based on Metabolomics[J]. Chinese Archives of Traditional Chinese Medicine, 2025 , 43 (12) : 47 -54 . DOI: 10.13193/j.issn.1673-7717.2025.12.008
慢性肾脏疾病(Chronic Kidney Diseases,CKD)被广泛认为是一个主要的公共卫生问题,影响着全球10%的人口健康,并且每年的患病率持续增加,数百万人因缺乏有效地治疗而死亡[1],到2040年预计CKD将成为全球第5大最常见的死亡疾病[2]。线粒体是存在于真核细胞内的由双层膜包被的细胞器。肾脏近端肾小管细胞占肾脏皮质细胞的比例高达90%,近端肾小管细胞是体内第二高密度线粒体场所,其线粒体含量和耗氧量仅次于心脏,其产生大量ATP的同时也需要消耗大量能量维持正常功能[3]。肾脏是能量代谢的重要场所。肾损伤早期已经导致线粒体活性氧(mitochondrial reactive oxygen species,mtROS)的过量产生,ATP产生的下降[4],促进炎症通路活化,炎性细胞因子和趋化因子释放增多,持续炎症启动肾纤维化进程。因此,线粒体功能障碍是肾纤维化发病过程中的关键环节。
目前“肾虚血瘀”是肾纤维化基本病因病机已成为医家共识,“瘀”贯穿肾纤维化病程始终。三七“活血化瘀、补虚强健”的功效与其病机高度契合。前期的研究表明,三七可以通过多途径减轻CKD微炎症状态、延缓肾纤维化进程的作用[5-7]。本研究基于代谢组学探讨三七对肾纤维化大鼠线粒体能量代谢的影响,阐明三七改善CKD肾脏能量代谢的作用机制。
SPF级雄性SD大鼠30只,体质量(220±30)g。实验所需动物从湖南斯莱克景达实验动物有限公司购买,公司许可证号为SCXK(湘)2019-0004。动物实验伦理审查批号:DW20221221-241。在广西中医药防治医学分子生物重点实验室饲养。
全自动生化分析仪(罗氏公司,cobas702),光学显微镜(日本尼康,Nikon Eclipse E100),多功能酶标仪(Molecular Devices,Flexstation3),透射电子显微镜(HT7800/HT7700,HITACHI),液相色谱仪(Thermo,Vanquish),质谱仪(Thermo,Orbitrap Exploris 120),HE染液(上海源科,G2006),ATP含量测定试剂盒(南京建成生物工程研究所,A095-1-1),ADP含量测定试剂盒(Abcam,ab83359),AMP含量测定试剂盒(Abcam,ab273275),ATP酶测定试剂盒(南京建成生物工程研究所,A016-2),线粒体呼吸链复合体Ⅰ/NADH-CoQ还原酶活性检测试剂盒(北京索莱宝公司,BC0515)线粒体呼吸链复合体Ⅱ/琥珀酸-辅酶Q还原酶活性检测试剂盒(北京索莱宝公司,BC3235),线粒体呼吸链复合体Ⅲ/CoQ-细胞色素C还原酶活性检测试剂盒(北京索莱宝公司,BC3245),线粒体呼吸链复合体Ⅳ/细胞色素C氧化酶活性检测试剂盒(北京索莱宝公司,BC0945),BCA试剂盒(碧云天,P0012S)。三七:中药配方颗粒(江苏省江阴市天江药业有限公司)。盐酸贝那普利5 mg/片(北京诺华制药有限公司,国药准字H20000292)。
参照前期研究中阿霉素肾纤维化大鼠模型的建立,镜检出现节段甚至球性肾小球硬化、球囊粘连、肾小管上皮细胞空泡变性、肾间质纤维化及炎症细胞浸润等病理改变则提示肾纤维化造模成功[7]。在阿霉素肾纤维化大鼠模型的基础上建立血瘀证模型[8]:在手术后6周,以0.1 mg/kg剂量盐酸肾上腺素注射液皮下注射于造模的大鼠,2 h后置于4℃冷水中游泳5 min,连续2周。以血液流变学改变评估血瘀证模型。
将30只清洁级SD雄性大鼠,数字表随机分为正常组、模型组、三七低剂量组、三七中剂量组、三七高剂量组、阳性对照组(贝那普利组),每组5只。正常组大鼠正常条件饲养,不造模;其余组大鼠按上法造模。造模完成后,阳性对照组大鼠每天给予贝那普利片给药,参考陈奇主编《中药药理实验方法学》体表面积等效剂量换算比率按人常用量5 mg/d,大鼠剂量5 mg×0.018=0.09 mg,200 g体质量大鼠的剂量为0.09 mg,0.09 mg/0.2 kg=0.45 mg/kg,溶于0.9%氯化钠溶液,按体质量灌胃给药。中药组按人和动物体表面积换算公式:大鼠中药给药剂量依据人-大鼠体表面积换算(1∶6.25),并按临床成人用药量的1、2、4倍剂量给药,三七低、中、高剂量组分别予以含生药0.45、0.9、1.8 g/kg三七颗粒水冲剂。正常组和模型组大鼠每天给予等体积的0.9%氯化钠溶液。各组皆按1 mL/100 g体质量灌胃,1次/d,连续8周。给药完成后腹主动脉采血后摘除左肾,放入液氮或固定液中保存。
肾组织经过固定液固定、脱水、包埋、染色,透射电镜观察肾组织线粒体结构。
严格按照ATP含量测定试剂盒、ADP含量测定试剂盒、AMP含量测定试剂盒、ATP酶测定试剂盒、线粒体呼吸链复合体Ⅰ/NADH-CoQ还原酶活性检测试剂盒、线粒体呼吸链复合体Ⅱ/琥珀酸-辅酶Q还原酶活性检测试剂盒、线粒体呼吸链复合体Ⅲ/CoQ-细胞色素C还原酶活性检测试剂盒、线粒体呼吸链复合体Ⅳ/细胞色素C氧化酶活性检测试剂盒操作分别检测ATP、ADP、AMP含量,Na+-K+-ATP酶、Ca2+-Mg2+-ATP酶活性、线粒体呼吸链复合体酶Ⅰ-Ⅳ活性。
(1)色谱条件:Thermo Vanquish(Thermo Fisher Scientific,USA)超高效液相系统,使用ACQUITY UPLC® HSST3(2.1×150 mm,1.8μm)(Waters,Milford,MA,USA)色谱柱,0.25 mL/min的流速,40℃的柱温,进样量2 μL。正离子模式,流动相为0.1%甲酸乙腈(C)和0.1%甲酸水(D),梯度洗脱程序为0~1 min,2% C;1~9 min,2%~50%C;9~12 min,50% ~98% C;12~13.5 min,98% C;13.5~14 min,98%~2% C;14~20 min,2% C。负离子模式,流动相为乙腈(A)和5 mmol/L甲酸铵水(B),梯度洗脱程序为0~1 min,2% A;1~9 min,2%~50% A;9~12 min,50%~98% A;12~13.5 min,98% A;13.5~14 min,98% ~2% A;14~17 min,2% A。
(2)质谱条件:Thermo Orbitrap Exploris 120质谱检测器(Thermo Fisher Scientific,USA),电喷雾离子源(ESI),正负离子模式分别采集数据。正离子喷雾电压为3.50 kV,负离子喷雾电压为-2.50 kV,鞘气30 arb,辅助气10 arb。毛细管温度325℃,以分辨率60 000进行一级全扫描,一级离子扫描范围100~1000 m/z,并采用HCD进行二级裂解,碰撞电压为30%,二级分辨率为15 000,采集信号前4离子进行碎裂,同时采用动态排除去除无必要的MS/MS信息。
(3)数据处理与分析:通过 Proteowizard 软件包(v3.0.8789)中MSConvert工具将原始质谱下机文件转换为mzXML文件格式。采用RXCMS软件包进行峰检测、峰过滤、峰对齐处理,得到物质定量列表,参数设置有bw=2,ppm=15,peakwidth=c(5,30),mzwid=0.015,mzdiff=0.01,method=“centWave”。采用公共数据库HMDB、massbank、LipidMaps、mzcloud、KEGG及自建物质库进行物质的鉴定,参数设置为<30 ppm。使用总峰归一化,即基于样本中单一代谢物定量值与所有代谢物的定量值总和的比例换算,实现归一化,进行数据校正,消除系统误差。
采用R软件包Ropls分别对样本数据进行主成分分析(PCA)、偏最小二乘判别分析(PLS-DA),并分别绘制得分图,展示各样本间代谢物组成的差异。用置换检验方法对模型进行过拟合检验。
R2X和R2Y分别表示所建模型对X和Y矩阵的解释率,Q2表示模型的预测能力,它们的值越接近于1表明模型的拟合度越好,训练集的样本越能够被准确划分到其原始归属中。根据统计检验计算P value值、OPLS-DA降维方法计算变量投影重要度(VIP)、fold change计算组件差异倍数,衡量各代谢物组分含量对样本分类判别的影响强度和解释能力,辅助标志代谢物的筛选。当P value值<0.05和VIP值>1时,认为代谢物分子具有统计学意义。
(4)通路分析:采用MetaboAnalyst软件包对筛选差异代谢分子进行功能通路富集和拓扑学分析。富集得到的通路采用KEGG Mapper可视化工具进行差异代谢物与通路图的浏览。
采用SPSS 22.0软件进行统计分析,计量资料符合正态分布且方差齐以均数±标准差表示,不符合正态分布或方差不齐以中位数(四分位间距)表示。符合正态分布方差齐的多样本比较采用单因素方差分析,组间两两比较采用LSD-t检验;不符合正态分布或方差不齐时采用秩和检验(Kruskalwallis),两两比较采用Wilcoxon法。P<0.05为差异有统计学意义。
大鼠肾组织透射电镜显示,正常组大鼠肾组织线粒体形态清晰,嵴膜系统完整,微绒毛形态清晰完整,自噬处于相对较低的水平;模型组细胞中出现大量空泡,线粒体数量减少,肿胀,嵴消失,微绒毛脱落,管腔内见大量细胞碎片,自噬小体数量明显增加;三七中、高剂量组及阳性对照组大部分细胞线粒体形态规整、完好,管腔内见少量细胞碎片,自噬体数量较少与正常对照组相比差异不明显;三七低剂量组与模型组相似,但是病变程度稍轻。见插页Ⅹ图1
与正常组比较,模型组,三七低、中、高剂量组和阳性对照组肾组织线粒体ATP含量显著降低(P<0.05);与模型组比较,三七中、高剂量组和阳性对照组肾组织线粒体ATP含量显著升高(P<0.05)。与正常组比较,模型组、三七低、中、高剂量组和阳性对照组肾组织线粒体ADP含量显著升高(P<0.05);与模型组比较,三七低、中、高剂量组和阳性对照组肾组织线粒体ADP含量显著降低(P<0.01)。与正常组比较,模型组、三七低、中剂量组和阳性对照组肾组织线粒体AMP含量显著升高(P<0.05),三七高剂量组AMP有升高趋势,差异无统计学意义;与模型组比较,三七低、中、高剂量组和阳性对照组肾组织线粒体AMP含量显著降低(P<0.05)。见表1
与正常组比较,模型组、三七低、中、高剂量组和阳性对照组肾组织Na+-K+-ATP、Ca2+-Mg2+-ATP酶活性明显降低;与模型组比较,三七低、中、高剂量组和阳性对照组肾组织中Na+ -K+ -ATP、Ca2+-Mg2+-ATP酶活性明显升高。见表2
与正常组比较,模型组、三七低、中、高剂量组和阳性对照组肾组织线粒体呼吸链复合体酶Ⅰ、Ⅳ活性显著降低;与模型组比较,三七中、高剂量组和阳性对照组肾组织线粒体呼吸链复合体酶Ⅰ、Ⅳ活性显著升高。与正常组比较,模型组、三七低、中剂量组肾组织线粒体呼吸链复合体酶Ⅱ活性显著降低;与模型组比较,三七低、中、高剂量组和阳性对照组肾组织线粒体呼吸链复合体酶Ⅱ活性显著升高。与正常组比较,模型组、三七低、中、高剂量组和阳性对照组肾组织线粒体呼吸链复合体酶Ⅲ活性显著降低;与模型组比较,三七低、中、高剂量组和阳性对照组肾组织线粒体呼吸链复合体酶Ⅲ活性显著升高。见表3
正、负离子模式下各组大鼠尿液色谱图(插页Ⅺ图2、插页Ⅺ图3),不同颜色代表不同组别。趋势越相似,说明重复性良好,结果可靠。
PCA作为一种无监督模式识别方式,能够反映数据的原始状态,在整个实验过程中,仪器具有良好的稳定性,样品处于受控状态,实验结果可靠。如插页Ⅺ图4所示,不同组别尿液样本在图中呈现出分离状态。正常组(N-Con)与模型组(Model)明显分离。
为了探究在大鼠尿液中显著改变的与肾纤维化相关的代谢产物,进一步通过PLS-DA方法对各组数据进行分析。如插页Ⅻ图5所示,正常组、模型组、阳性对照组、三七低、中、高剂量组在所建立的数据模型中表现出良好的拟合度和预测能力(正离子:R2 X:0.357,R2 Y:0.997,Q2:0.914;负离子:R2 X:0.345,R2 Y:0.997,Q2:0.882)。
(1)差异代谢物火山图:如插页插页ⅩⅢ图6所示,模型组与正常组总差异代谢物数为255,其中上调差异代谢物数为114,下调差异代谢物数为141;模型组与三七低剂量组总差异代谢物数为204,其中上调差异代谢物数为104,下调差异代谢物数为100;模型组与三七中剂量组总差异代谢物数为162,其中上调差异代谢物数为56,下调差异代谢物数为106;模型组与三七高剂量组总差异代谢物数为202,其中上调差异代谢物数为99,下调差异代谢物数为103;模型组与阳性对照组总差异代谢物数为181,其中上调差异代谢物数为61,下调差异代谢物数为120。
(2)差异代谢物筛选结果:基于VIP值、t检验的P值和离子在组间的变化倍数(foldchange,FC)筛选差异物质。当P value值<0.05和VIP值>1时,认为代谢物分子具有统计学意义。各实验组相比有154个差异基因,其中与正常组相比,模型组共有25个代谢物显著下调、48个代谢物显著上调(表4);三七各剂量组与模型组相比,筛选出主要的代谢物11个,包括D-Arabitol、1H-Indole-3-acetamide、Biotin、Moupinamide、Allantoic acid、trans-Ferulic acid、6-Methylmercaptopurine、6-Methyladenine、4-Hydroxy-2-quinolone、3-Aminopentanedioate和Morin(插页Ⅻ图7、插页ⅩⅣ图8-图9、插页ⅩⅤ图10-图11、插页ⅩⅥ图12-图13、插页ⅩⅦ图14-图15、插页ⅩⅧ图16-图17)。
基于KEGG代谢通路,采用MetPA数据库分析各组差异代谢物相关代谢通路。结果 如表4和插页ⅩⅨ图18所示,潜在代谢标记物主要参与78条代谢通路,其中醛固酮调控的钠重吸收(Aldosterone-regulated sodium reabsorption)代谢通路P值小于0.05,Imapact值分为0.3,说明本次检测到的差异代谢物对该通路的影响显著。
线粒体是体内ATP合成的主要场所,ATP生成与呼吸作用的耦合被称为氧化磷酸化,氧化磷酸化是细胞代谢的中心,是真核生物能量生产的关键,被称为“细胞动力工厂”。线粒体氧化磷酸化依赖于线粒体呼吸链,它由4种主要的酶复合物和2个移动电子载体组成。同时,三羧酸循环、钙信号通路的稳态、细胞凋亡、活性氧(reactive oxygen species,ROS)生成、脂肪酸氧化代谢等线粒体功能由构成氧化磷酸化酶复合体维持。细胞内ATP参与能量转移,而在细胞外环境中ATP作为损伤相关分子模式(damage-associated molecular pattern,DAMP)并刺激炎症反应,尽管ATP的释放会促进损伤,但这一过程对于促进组织修复也是必不可少[9]。在早期CKD阶段已存在线粒体功能异常,ATP释放增加。有研究结果表明,在5/6肾切除CKD模型中,模型组观察到自第2天以来复合体Ⅰ活性永久性降低,术后第7、14和28天复合体Ⅲ活性下降,早期肾组织线粒体β-氧化降低,提示线粒体生物功能损伤是肾损伤的早期事件,线粒体损伤时间上的持续性加重了CKD的发展[10]。肾损伤早期mtROS的过量产生,特别是由于线粒体DNA拷贝数的减少,导致线粒体膜电位的丧失和ATP产生的下降[4]。糖尿病小鼠肾脏线粒体DNA拷贝数持续下降,伴有ATP产生下调[11]。转化生长因子-β1(Transforming growth factor-β1,TGF-β1)处理的肾巨噬细胞线粒体表现出超氧化物水平增加,ATP生成减少,巨噬细胞通过调节磷酸酶和紧张素同源诱导激酶(phosphatase and tensin homolog-induced kinase1,PINK1)/线粒体融合蛋白(mitofusin-2,MFN2)/E3泛素连接酶(E3 ubiquitin ligase encoded by Prkn,parkin)介导的线粒体自噬通路对肾纤维化起保护作用[12]。我们的研究结果表明在血瘀证阿霉素肾纤维化大鼠肾组织中ATP水平显著下降,这与WANG等[13]研究发现CKD组线粒体ATP水平和基底线粒体耗氧率显著降低的结果一致。我们的研究发现,ATP水平下降可能与线粒体生物功能损伤,呼吸链复合体Ⅰ、复合体Ⅱ、复合体Ⅲ、复合体Ⅳ活性下降,ATP酶活性降低密切相关。
代谢组学是继基因组学、蛋白质组学后的一门新兴学科,是一门系统研究生物体某一部位细胞、血液、体液小分子代谢产物的科学,其主要科研方法是收集和筛选出代谢产物,然后比较不同代谢物之间的差异,反映机体不同生理、病理状态下或内外因素影响下代谢物的代谢轮廓变化,得出代谢物的变化趋势和规律,以进一步揭示某种病理现象和疾病发病机制或者药物的作用机制[14]。肾脏是机体重要的代谢场所,各类代谢终产物的改变反映肾脏疾病的发生发展,代谢组学为肾脏疾病的研究提供了新的思路和方向,相关研究日益增多,由此发现的代谢物有些已被证实可以作为肾脏疾病诊断及预后的生物学标志物应用于临床,如肾损伤分子-1(kidney injurymolecule 1,KIM-1)[15]、中性粒细胞明胶酶相关脂质运载蛋白(neutrophil gelatinase-associated lipocalin,NGAL)[16]等。本研究进行了三七低、中、高剂量组及模型组和正常组尿液代谢物分析对比,筛查出11个差异尿液代谢产物。目前的研究表明其中一些代谢差异物参与CKD发生发展进程。Ferulic acid可以减轻糖尿病肾病(diabetic nephropathy,DN)大鼠肾损伤,可能机制是通过调节丝裂原激活的蛋白激酶/MAP激酶(mitogen-activated protein kinase,MAPK)、核因子-κB(nuclear factor kappa,NF-κB)通路、内源性和外源性凋亡通路,减轻炎症反应、自噬损伤和肾小管细胞凋亡[17]。临床运用中发现Ferulic acid联合厄贝沙坦可以明显减轻慢性肾衰竭(chronic renal failure,CRF)患者体内血清炎性因子,改善肾功能[18]。Morin通过抗炎、抗凋亡、抗氧化和激活自噬保护顺铂诱导的肾损伤[19]。腺嘌呤诱导的CKD小鼠模型中,Morin通过减少基质金属蛋白酶-2(matrixmetalloproteinase-2,MMP-2)、MMP-9蛋白的表达,降低单核细胞趋化蛋白-1(monocyte chemoattractant protein-1,MCP-1)和环氧合酶-2(cyclooxygenase-2,COX-2)表达,从而降低炎症水平,改善肾功能[20]。儿童CKD 1~2期尿液中Arabitol含量比CKD 3~5期显著升高,这与本研究正常组尿液代谢物中Arabitol含量比模型组显著升高的研究结果类似[21]。一项研究发现DN患者与正常人相比较,其血清代谢物中6-Methylmercaptopurine差异显著,可作为DN早期识别的潜在生物标志物[22]
本研究进一步对CKD大鼠各实验组尿液代谢物KEGG通路富集分析结果显示醛固酮调控的钠重吸收通路差异显著。这与SZMIT S等[23]的研究结果相似,他运用转录组学对急性心力衰竭肌酐正常与升高的患者外周血基因筛查并进行通路分析,显示调控最显著的信号通路是醛固酮调控的钠重吸收,进一步研究发现患者Na+/K+-ATP酶的表达差异明显。醛固酮是CKD肾纤维化病理过程的关键因子,作用于肾血管、肾细胞(肾小球系膜细胞、足细胞、血管平滑肌细胞、小管上皮细胞、间质成纤维细胞)和浸润性炎症细胞,诱导ROS产生,上调上皮生长因子受体(epithelial growth factor receptor,EGFR)、1型血管紧张素(angiotensin type 1,AT1)受体的表达,激活NFκB、激活蛋白1(activin 1,AP-1)、TGF-β等的表达,最终导致肾脏纤维化[24]。醛固酮诱导的肾损伤以肾小管为主,尤其以远端肾小管明显[25]。小鼠注射醛固酮后足细胞和肾小球中线粒体膜电位、ATP水平和线粒体DNA拷贝数下降[26]。Na+在细胞生理功能中发挥重要作用,除了维持细胞外液和渗透压、影响细胞内外体液分布、参与维持酸碱平衡、维持细胞内外Na+-K+以及ATP的利用和生成等,2020年HERNANSANZAGUSTÍN P等[27]研究发现线粒体Na+/Ca2+通道激活促进Na+进入基质,随后Na+与磷脂相互作用,降低线粒体内膜流动性和游离泛醌在复合物Ⅱ和复合物Ⅲ之间的迁移率,在复合物Ⅲ中产生超氧化物,这表明Na+通过与磷脂相互作用来控制线粒体氧化磷酸化系统功能,影响ATP的合成过程。因此,醛固酮诱导的能量代谢障碍是CKD肾纤维化的重要因素,醛固酮调控的钠重吸收通路是CKD肾纤维化能量代谢的主要调控途径。
本研究结果提示三七可以提高血瘀证CKD大鼠肾组织ATP含量及Na+-K+-ATP酶、Ca2+-Mg2+-ATP酶,线粒体呼吸链复合体酶Ⅰ、Ⅱ、Ⅲ、Ⅳ活性。三七通过调节差异尿液代谢产物Ferulic acid、Morin、Arabitol、Acetamide、Biotin、Allantoic acid、6-Methylmercaptopurine、4-Hydroxy-2-quinolone、Aminopentanedioate、6-Methyladenine和Moupinamide的代谢,调控醛固酮调节Na+重吸收通路,从多靶点、多途径改善血瘀证CKD大鼠的线粒体能量代谢,发挥抗肾纤维化作用。
  • 国家自然科学基金地区科学基金项目(81960866)
  • 国家中医药管理局高水平中医药重点学科建设项目-中医内科学(zyyzdxk-2023166)
  • 中医学广西一流学科项目(桂教科研〔2022〕1号)
参考文献 引证文献
排序方式:
[1]
NEUEN B L,CHADBAN S J,DEMAIO A R,et al. Chronic kidney disease and the global NCDs agenda[J]. BMJGlob Health20172(2):e000380.
[2]
LI P K,GARCIA-GARCIA G,LUI S F,et al. Kidney health for everyone everywhere-from prevention to detection and equitable access to care[J]. Pediatr Nephrol202035(10):1801-1810.
[3]
LUTHER T,BÜLOW-ANDERBERG S,PERSSON P,et al. Renal mitochondrial dysfunction in ovine experimental sepsis-associated acute kidney injury[J]. Am JPhysiol Renal Physiol2023324(6):F571-F580.
[4]
BAIM,CHEN H,DING D,et al. MicroRNA-214 promotes chronic kidney disease by disrupting mitochondrial oxidative phosphorylation[J]. Kidney Int201995(6):1389-1404.
[5]
黄志敏,黄仁发,唐宇,. 基于JAK/STAT信号通路观察三七注射液对阿霉素诱导的肾纤维化大鼠炎症因子的影响[J]. 中国中西医结合肾病杂志201920(5):379-382.
[6]
黄志敏,黄仁发,唐宇,. 基于肠肾轴理论探讨三七注射液对慢性肾脏病大鼠肠黏膜功能和肠道菌群的影响[J]. 中华中医药学刊202139(9):156-159.
[7]
黄志敏,黄仁发,唐宇,. 三七注射液对阿霉素肾纤维化大鼠炎症启动因子和终止因子的影响[J]. 中华中医药学刊202139(5):175-178.
[8]
赵玲,魏海峰,李雅莉,. 从血液流变学的改变分析肾上腺素致血瘀证大鼠模型的建立[J]. 中西医结合心脑血管病杂志20108(2):188-1903.
[9]
DWYER KM,KISHORE BK,ROBSON SC. Conversion of extracellular ATP into adenosine:amaster switch in renal health and disease[J]. Nat Rev Nephrol202016(9):509-524.
[10]
HUIY,LU M,HAN Y,el at. Resveratrol improvesmitochondrial function in the remnant kidney from 5/6 nephrectomized rats[J]. Acta Histochem2017119(4):392-399.
[11]
AKHTAR S,SIRAGY H M. Pro-renin receptor suppressesmitochondrial biogenesis and function via AMPK/SIRT-1/PGC-1alpha pathway in diabetic kidney[J]. PLoSONE201914(12):e225728.
[12]
BHATIA D,CHUNG K P,NAKAHIRA K,et al. Mitophagy-dependentmacrophage reprogramming protects against kidney fibrosis[J]. JCI Insight20194(23):e132826.
[13]
WANG D T,YANG Y J,ZOU X H,et al. Curcumin ameliorates CKD-induced mitochondrial dysfunction and oxidative stress through inhibiting GSK-3βactivity[J]. JNutr Biochem202083:108404.
[14]
杨倩春,李思宁,陈硕,. 代谢组学的运用及其研究进展[J]. 临床合理用药杂志202013(2):176-178.
[15]
BRILLAND B,BOUD'HORSC,WACRENIER S,etal. Kidney injury molecule1(KIM-1):a potential biomarker of acute kidney injury and tubulointerstitial injury in patientswith ANCA-glomerulonephritis[J]. Clin Kidney J202316(9):1521-1533.
[16]
ROMEJKO K,MARKOWSKA M,NIEMCZYK S. The review of current knowledge on neutrophil gelatinase-associated lipocalin(NGAL)[J]. Int JMol Sci202324(13):10470.
[17]
MA R Y,HE Y H,FANGQ,etal. Ferulic acid ameliorates renal injury via improving autophagy to inhibit inflammation in diabetic nephropathymice[J]. Biomed Pharmacother2022153:113424.
[18]
陈璐. 阿魏酸钠联合厄贝沙坦对慢性肾功能衰竭患者血清炎性因子、Hcy、PTH及β2-MG的影响[J]. 中国医药科学20199(19):32-35.
[19]
SINGH M P,CHAUHAN A K,KANG S C. Morin hydrate ameliorates cisplatin-induced ER stress,inflammation and autophagy in HEK-293 cells and mice kidney via PARP-1 regulation[J]. Int Immunopharmacol201856:156-167.
[20]
SINGH M P,SHARMA C,CHU S. KANGMorin hydrate attenuates adenine-induced renal fibrosis via targeting cathepsin D signaling[J]. Int Immuno-pharmacol202190:107234.
[21]
VANLEDE K,KLUIJTMANS L A J,MONNENS L,et al. Urinary excretion of polyols and sugars in children with chronic kidney disease[J]. Pediatr Nephrol201530(9):1537-1540.
[22]
ZHANG H,ZUO JJ,DONG SS,etal. Identification of potential serum metabolic biomarkers of diabetic kidney disease:a widely targeted metabolomics study[J]. Journal of diabetes research20202020:3049098.
[23]
SZMIT S,JANK M,MACIEJEWSKIH,et al. White blood cell transcriptome correlates with renal function in acute heart failure[J]. Int Heart J201253(2):117-124.
[24]
SHRESTHA A,CHE R,ZHANG A. Role of aldosterone in renal fibrosis[J]. Adv Exp Med Biol20191165:325-346.
[25]
BALHORN R,HARTMANN C,SCHUPP N. Aldosterone induces DNA damage and activation of Nrf2 mainly in tubuli ofmouse kidneys[J]. Int JMol Sci202021(13):4679.
[26]
ZHU C,HUANG S,YUAN Y,et al. Mitochondrial dysfunction mediates aldosterone-induced podocyte damage:a therapeutic target of PPARγ[J]. Am JPathol2011178(5):2020-2031.
[27]
HERNANSANZ-AGUSTÍN P,CHOYA-FOCES C,CARREGALROMERO S,et al. Na+ controls hypoxic signalling by the mitochondrial respiratory chain[J]. Nature2020586(7828):287-291.
2025年第43卷第12期
PDF下载
62
30
引用本文
BibTeX
文章信息
doi: 10.13193/j.issn.1673-7717.2025.12.008
  • 首发时间:2026-04-29
  • 出版时间:2025-12-10
补充材料
相关文章
文章信息
作者
出版历史
基金
国家自然科学基金地区科学基金项目(81960866)
国家中医药管理局高水平中医药重点学科建设项目-中医内科学(zyyzdxk-2023166)
中医学广西一流学科项目(桂教科研〔2022〕1号)
作者信息
    1.广西中医药大学第一附属医院,广西中医药防治医学分子生物重点实验室,广西 南宁 530023
    2.广西中医药大学第一附属医院仁爱分院,广西 南宁 530001

通讯作者:

吴金玉(1965-),女,广东广州人,教授、主任医师,博士研究生导师,博士,研究方向:中医药防治风湿免疫疾病。E-mail:
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/zhzyyxk/CN/10.13193/j.issn.1673-7717.2025.12.008
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数

Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)

Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏